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ABSTRACT 
Previous studies demonstrated that cognitive function was impaired in diabetic 
patients. Subsequent behavioral and electrophysiological studies also showed 
cognitive deficits in experimentally-induced diabetic animals. However, the 
mechanisms by which chronic hyperglycemia impairs cognitive function are not well 
understood. Hippocampus is a brain area that plays an important role in the cognitive 
function of learning and memory formation. It is also known that glutamate 
receptors, retrograde messengers, y-amino butyric acid (GABA) receptors play a 
critical role in learning and memory. The overall aim of the present investigation was 
to examine the effect ofdiabetes on gene expression of genes, whose encoded product 
may be of importance in the mechanism of learning and memory formation in � 
hippocampus. “ 
Diabetes was induced by injecting male Sprague-Dawley rats of about 250g 
body weight with 75mgy'kg streptozotocin and they were sacrificed after 4, 6，8, 10 or 
12 weeks. Hippocampal tissues were collected and total RNAs were extracted. 
Expression of genes of interest was measured using a semi-quantitative ^^P-labeled 
dCTP reverse transcription-polymerase chain reaction (RT-PCR) approach. Semi-
quantitation o f c D N A with Oligreen fluorescence dye was used to correct the unequal 
amount of RT-product added into the PCR tubes. The radio-labeled PCR-products 
were separated by electrophoresis in a 8% native polyacrylamide gel and quantified 
with a BioRad Phosphorimager. 
GluR6 mRNA were decreased after 10 weeks of diabetes and recovered 
completely with insulin therapy. The amounts of kainate receptor subtype 1 (KA1) 
i 
mRNA were also decreased after 10 weeks of diabetes, however, no recovery was 
evident after insulin therapy. 
mGluRl mRNA were reduced after 10 weeks of diabetes and recovered after 
insulin therapy. mGluR2 mRNA was increased significantly after STZ-injection. In 
contrast, mGluR3 mRNA were reduced, however, they did not recover after insulin 
therapy. 
The heme oxygenase subtype 1 (H01) mRNA, inducible form of the synthase 
ofcarbon monoxide (CO), as reduced after 10 weeks of diabetes and almost recovered 
ii 
after insulin therapy. The expression of phospholipase A2 (PLA2), a synthase of both 
ff 
arachidonic acid (AA) and platelet activating factor (PAF), was also suppressed after 
10 weeks of diabetes, however, no remedy after insulin therapy. Diabetes also 
induced a downregulation of calcium-sensing receptor (CSR) mRNA levels. 
In contrast, diabetes induced an upregulation of some GABA receptor subtype 
expression in hippocampus. The GABAAal mRNA was increased after 8 weeks of 
diabetes. The GABAAa2 gene transcript was increased after STZ-treatment. Besides, 
the amounts of GABAAOt3 mRNA were also increased after 4 and 10 weeks of 
diabetes. Insulin therapy did not alter the effect of diabetes on GABAAa3 mRNA 
expression. The transcription of GABAAOc4 and glutamic acid decarboxylase 65 
(GAD65) also increased significantly after STZ-injection. . 
The mRNA levels of protein phosphatase 2A (PP2A) and PP2B were 
increased after STZ-injection. Diabetes seemed to induce an upregulation of enzyme 
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1. Introduction 
1.1. Diabetes meIIitus 一 general introduction 
Diabetes mellitus is the fourth leading causes of death by disease. It is 
characterized by inadequate metabolism of sugars and starch absorbed in the diet, 
leading to symptoms of thirst, emaciation and high levels of glucose in both the 
blood and urine. It is associated with long-term complications that affect almost 
every major part of the body. It contributes to blindness, heart disease, strokes, 
kidney failure, amputations, and nerve damage. Uncontrolled" diabetes can 
complicate pregnancy, and birth defecfs are more common in babies born to 
women with diabetes. 
Some people misunderstand that diabetes usually is found in the developed 
countries like United State. But as a recent WHO report puts it, diabetes is now a 
Third World problem. The 1997 World Health Report indicated that developing 
countries would bear the bmnt of the diabetes epidemic in the 2T' century. In the 
report，approximately 135 million adults were estimated to be with diabetes in 
1995. By the year 2025, the figure is expected to rise to 300 million, an increase of 
approximately 120%. Whereas the rise will be of the order of 40% in the 
developed countries, it will be 170% in the developing countries. As a result, more 
than 80% ofpeople with diabetes will be found in the developing countries by the 
year 2025. 
(A) The classification of diabetes mellitus 
According to the report of the Expert Committee on the diagnosis and 
classification of diabetes mellitus 1997, the disease was classified into four major 
types: Type 1 diabetes, Type 2 diabetes, Other specific types and Gestational 
1 
diabetes mellitus (GDM) [The Expert Committee on the Diagnosis and 
Classification ofDiabetes Mellitus, 1997]. 
Type 1 diabetes, previously named insulin-dependent diabetes, or juvenile-
onset diabetes, results from a cellular-mediated autoimmune destruction of the P-
cells of the pancreas [Atkinson and Maclaren, 1994]. In this form of diabetes, the 
rate of P-cell destruction is quite variable, being fast mainly in infants and children 
and slow mainly in adults [Zimmet et al., 1994]. Autoimmune destruction of P_ 
cells has multiple genetic predispositions and is also related to environmental 
factors that are still poorly defined. “ 
Type 2 diabetes, previously referred to as non-insulin-dependent diabetes, 
or adult-onset diabetes, is a term used for individuals who have insulin resistance 
and usually have relative (rather than absolute) insulin deficiency [Turner et al., 
1979]. Most patients with this form of diabetes are obese, and obesity itseIfcauses 
some degree ofinsulin resistance [Bogardus etal., 1985]. 
Other specific types of diabetes include genetic defects of the p-cell, genetic 
defects in insulin action, disease of the exocrine pancreas, endocrinopathies, drug-
or chemical-induced diabetes, infections, Uncommon forms of immune-mediated 
diabetes or other genetic syndromes sometimes associated with diabetes. 
Gestational diabetes mellitus (GDM) is defined as any degree of glucose 
intolerance with onset or first recognition during pregnancy. The definition applies 
regardless of whether insulin or diet modification is used for treatment, or whether 
the condition persists after pregnancy. In the majority of cases of GDM, glucose 
regulation will return to normal after delivery. 
(B) Diabetic Neuropathy 
2 
Diabetic neuropathy is a common complication of diabetes that may be 
associated both with considerable morbidity (painful polyneuropathy, neuropathic 
ulceration) and mortality (autonomic neuropathy). 
Peripheral and autonomic nervous systems are significantly affected by the 
abnormal metabolism of glucose in diabetes mellitus. 
From animal studies on streptozotocin-induced diabetic rats or the 
genetically diabetic Bio-Breeding (BB) rats, many pathological changes are 
observed in the peripheral nerves [Chakrabarti, 1999]. Loss ofmyelinated fibres in 
the vagus nerve, with enlargement and vacuolation of neurones is also observed in 
subjects with autonomic neuropathy [Duchen et al., 1980]. Substantial evidence 
indicates that the development of neuropathy is related to the blood glucose level. 
Greene etal. (1987) suggested that hyperglycemia-induced nerve dysfunction (e.g. 
reduced nerve conduction velocity) and damage may be mediated through sorbitol 
accumulation, myo-inositol depletion and reduced Na+K+-ATPase activity. Besides 
of the change of this polyol pathway, long-term exposure of nerve myelin protein 
to hyperglycemia, in vivo and in vitro, led to the formation of advanced glycation 
end products and an alteration in myelin-macrophage interactions. This may 
contribute to the segmental demyelination associated with diabetes of peripheral 
nerve [Vlassara et al., 1984]. Glucotoxicity is not tissue specific, although the 
severity of organ system dysfunction in diabetes is highly variable [Mooradian, 
1988]. 
In contrast to peripheral or autonomic neuropathy, chronic diabetic 
complication of central nervous system (CNS) is not widely known. Recently, the 
focus of research on diabetic neuropathy has been shifted to CNS. Considerable 
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evidence suggests that diabetes can alter CNS function. The possible causes 
included the structural changes in CNS, dysfunction of blood-brain barrier (BBB), 
or biochemical and neuroendocrine alterations in CNS. Degeneration of ganglion 
cells and demyelination and loss of axons have been observed in diabetic patients. 
Calcium deposition of small blood vessels and capillary dropout in cerebral cortex 
has also been found in diabetics. These structure changes may contribute to the 
alterations in CNS function in subjects with diabetes [Mooradian, 1997]. 
The BBB plays an important role in maintaining the normal function of the 
it 
brain. Specific transport carriers in the BBB deliver useful nutrients to the brain. 
In addition to transport function, it can also prevent various toxic compounds in 
the circulation from gaining access to the brain. Besides, the BBB is abundant of 
antioxidative enzymes [Tayarani etal., 1987], which could ameliorate the exposure 
of the CNS to oxidative stress generated systemically. The barrier function of 
BBB was found to be well maintained in diabetes [Lorenzi et al., 1986; Jakobsen et 
al., 1987; Lorenzi, 1990], but the transport function was selectively altered. The 
BBB transport of glucose, choline, vitamin C, and sodium through the BBB were 
reduced in diabetes [Mooradian and Morin, 1991; McCall et al., 1982; Mooradian, 
1987; Pardridge et al‘, 1990]. Previous studies have shown that the principal 
glucose transporter isoform within the BBB is glucose transporter 1 (GLUT1) ‘ 
[Lutz and Pardridge, 1993]. It was found that both the levels o f G L U T l mRNA 
and protein, as well as the length of its poly(A) tail are also reduced in diabetes 
[Shah et al., 1997]. Increased accumulation oflipid peroxidative by-products and 
reduced antioxidant activity were found in cerebral microvessels of diabetic rats. 
Besides, the post-translational modification of proteins such as glycation and 
4 
malondialdehyde modification was also reported in BBB [Mooradian et al., 1994]. 
In addition, diabetes could alter the beta-adrenergic neurotransmission at the BBB 
as evidenced by reduced beta adrenergic receptor number in cerebral microvesseIs 
[Magnoni et al., 1984]. All these changes are causes of diabetic alterations in BBB 
function. 
In addition, biochemical and neuroendocrine alterations have been found in 
CNS of diabetic animals. The levels of amino acids in CNS tissue, some of which 
are precursors of various neurotransmitter, were altered in diabetic animals 
[Crandall and Fernstrom, 1983; Glanville and Anderson, 1985]. The serotonin 
content of hypothalamus and brainstem was reduced and increased dopamine level 
in the hippocampus was also found in diabetic animals [Chu et al., 1986]. Besides, 
neuroendocrine changes are also found in diabetes. In experimental diabetic 
animals, reduced release of gonadotropin releasing hormone and a decrease 
number ofpituitary gonadotropic releasing hormone (GnRH) receptors in pituitary 
were found [Bowton et al., 1986]. 
1.1.1. Animal models of diabetes 
Diabetic animals have contributed much to our understanding o f the causes 
and consequences of diabetes. Over a century ago, it was found that removal of 
the pancreas from a dog produced a condition clinically indistinguishable from 
diabetes mellitus in humans. These models were also important to develop 
strategies for potential treatment of the disease. For example, specific etiological 
factors and/or genetic backgrounds can be selected and combined to produce a 
particular type of experimental diabetes, allowing the researcher to explore 
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particular biochemical or anatomical alterations, which may provide target sites for 
pharmacological interactions. 
1.1.2. Streptozotocin-induced diabetes (SID) 
Streptozotocin [2-deoxy-2-(3-methyl-3-nitrosourea) 1 -D-glucopyranose] is 
a nitrosourea derivative isolated from the mould Strep_yces achromogenes. It is 
a broad-spectrum antibiotic. Upjoin Laboratories first detected the diabetogenic 
response to STZ during the testing of such potential antibiotic from this organism. 
Besides, administration of a single intravenous dose of STZ could produce P_cell 
necrosis and ensure diabetic state in rats [Rodrigues et al., 1999] 
Both of the alloxan and streptozotocin are commonly used chemical agents 
to induce diabetes. In fact, they share certain similar cytotoxic effects on P-cell; 
namely, damage to the p-celI membrane, the induction of DNA strand breaks, 
NAD depletion and the activation of poly(ADP-ribose) synthetase. However, 
there is still a difference between alloxan and streptozotocin with respect to the 
initial mechanism of their toxic actions on P-cell DNA. It was suggested that 
alloxan acts through the formation of a hydroxyl radical that is produced by the 
interaction between superoxide and peroxide [Okamoto, 1996]. Superoxide 
dismutase and cataIase remove superoxide and peroxide respectively, and hence 
can inhibit the formation of the hydroxyl radical. In contrast, STZ-induced islet 
DNA strand breaks were unaffected by radical scavengers, such as superoxide 
dismutase and catalase [Uchigata et al., 1982]. Therefore, it is unlikely that STZ 
acts on islet DNA through the formation of oxygen radicals. The STZ-induced 
breakage of DNA was suggested to be associated with the alkylating activity or 
6 
nitric oxide generating activity of the agent [Wilson et al., 1988; Turk et al., 1993]. 
Besides, the cytotoxic effect of STZ was related to specific recognition of the drug 
in p-cells as a transported substrate by GLUT2 [Schnedl et al., 1994]. 
In this study, STZ was selected as the chemical agent to produce 
experimental diabetes, because it has greater selectivity of P-cells [Rodrigues et al., 
1999]. Besides, the mortality rate of the STZ diabetic animals is lower (effective 
diabetogenic dose of STZ is four to five times less than its lethal dose) [Hoftiezer 
and Carpenter, 1973]. Furthermore, the half-life of STZ in the body is longer, 
lasting about 15 minutes [Agarwal, 1980].产 
1.1.2.1. Mechanism of the diabetogenic effect of STZ 
STZ (Figure 1.1) is composed of a glucose molecule with a highly reactive 
nitrourea moiety that is necessary for DNA alkylation. The glucose moiety directs 
this agent to the pancreatic P-cell, where it binds to a membrane transporter to 
generate structural damages (j3-cell necrosis) [Rodrigues et al., 1999]. At the 
intracellular level, two major processes are likely responsible for P-cell death: (1) 
methylation and (2) nitric oxide production. 
The cytotoxic effect of STZ results from the generation of highly reactive 
carbonium ions (CH3+)，from decomposition of its nitroso moiety. The CH3+ ions 
cause DNA breakage by alkylating DNA bases at different positions [Uchigata et 
al., 1982], resulting in activation of the poly(ADP-ribose) synthetase, a nuclear 
enzyme that requires NAD^, and increased activity of this enzyme could lead to 
depletion of intracellular NAD^ [Yamamoto etal., 1981]. NAD+ depletion results 
in the inhibition of the cyclic ADP-ribose-mediated Ca^^ mobilization from the 
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Figure 1.1 Chemical structure of2-deoxy-2[((methylnitrosoamino)carbonyI)-
amino]-D-glucopyranose (streptozotocin). • 
8 
endoplasmic reticulum. This in turn could impair the ability of the p-cell to 
synthesize insulin [Okamoto, 1981]. 
Involvement of NO has also been proposed as a possible mechanism for 
mediating the diabetogenic effects of STZ [Kwon et al., 1994]. STZ, through 
production of superoxide, would generate peroxynitrite. The latter would 
dissociate into NO, thus leading to P-cell DNA damage and activating cell repair 
mechanism by depletion of intracellular NAD+. 
1» 
1.1.2.2. Administration ofSTZ -
Diabetes induced by a single intraperitoneal injection of streptozotocin is 
probably the most widely used experimental model of IDDM. After a single 
intraperitoneal dosage of 50-60 mg/kg, plasma insulin levels typically fall to 10-
30% of normal level, leading to hyperglycemia (20-30 -mmol/L), polyuria, 
polydipsia and weight loss [Bone and Gwilliam, 1997]. Higher dosages induce 
more profound insulin deficiency. For example, Giorgino et al. (1992) induced 
diabetes (lOOmg/kg STZ) in 200g male Sprague-Dawley rats by the intraperitoneal 
route, the plasma glucose levels of the injected animals were markedly elevated, 
plasma insulin decreased about 50% of control. There was also an approximately 
20% decline in body weight within 5 days following STZ treatment. In the present 
study, a single intraperitoneal injection of streptozotocin (75 mg/kg) was used to 
induce diabetes. All the streptozotocin-induced diabetic (SID) rats should have 
blood glucose levels greater than 20 mmol/L. 
1.2. Impairment of cognitive function in diabetes meIIitus 
9 
Cognitive function is one of the important functions in human and as well 
as animal CNS. In one study, poor diabetic control or presence of peripheral 
neuropathy was predictor of deficiency in memory retrieval [Perlmuter et al., 
1984]. From an early study, it was proposed that memory dysfunction would be a 
distinctive feature of diabetic mellitus [Prescott et al., 1990a]，and this has been 
confirmed in subsequent studies both in type 1 and type 2 diabetes. Type 1 
diabetic patients were found to have poorer memory, attention and slower rate of 
nonverbal responding compare with nondiabetic controls [Ryan et a/.,,.1984; Ryan 
et al., 1985; Mooradian et al., 1988]. Type 2 diabetic patients also showed a 
broadly similar pattern of cognitive deficits as type 1 diabetic patients, but they 
were conspicuously impaired in tests of learning and remembering [Meuter et al., 
1980]. In addition, hyperinsulinaemia always precedes the development of type 2 
diabetes in normoglycaemia. There was also epidemiological evidence for 
cognitive dysfunction in hyperinsulinaemia [Kuusisto et al., 1993]. Although the 
exact mechanisms are not known, insulin per se could have direct effects on 
cognitive function, since insulin receptors have been found in the rat hippocampus 
[Dore etcd., 1997]. Insulin reduced cholinergic activity in striatal neurone cultures 
[Brass et al., 1992] and accelerated turnover of monoamines in the brain [Shimizu 
and Bray, 1990; Holmes et al., 1989]. Insulin could, therefore, alter cognitive 
fbnction by reducing cholinergic activity or by affecting monoamines metabolism. 
Insulin might also increase sympathetic activity, which may lead to cognitive 
dysfunction [Rowee/ al, 1981]. 
The hippocampus is known to play an important role in human learning and 
pyramidal layer of hippocampus is particularly susceptible to damage as a result of 
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hypoglycemia induced by insulin injection [Richardson, 1990]. It is believed that 
chronic hypoglycemia can lead to memory deficiency. Subsequent research has 
shown that experimentally induced hypoglycemia was associated with poorer 
performance across a broad range of cognitive tasks including associative learning, 
attention, mental flexibility [Draelos et al., 1995], reaction time [Herold et al., 
1985], visual tracking, visuomotor speed, concentration, planning ability [Hoffman 
et al., 1989], and naming performance [Holmes et al., 1984]. Impaired declarative 
memory and spared nondeclarative memory functioning have also been found in 
severe hypoglycemic patients [Hershey et al,, 1997]. 
In addition to hypoglycemia, hyperglycemia per se is also suggested leading 
to cognitive dysfunction. But it is still controversial because the number of 
behavioral studies in hyperglycemic patients and rodents was limited, and the 
results had been equivocal. Experimentally induced acute hyperglycemia may have 
no effect upon either cognitive function [Hoffman et al., 1989] or 
electrophysiological measures of cortical efficiency [Mooradian et al., 1988]. 
Moreover, some studies have even found improved performance in memory tasks 
with raised blood glucose levels [Gold, 1986; Gold et al., 1986; Hall et al., 1989]. 
This has led researchers to embrace the null hypothesis and assume that there is no 
association between hyperglycemia and cognitive dysfunction. This hypothesis 
may have been premature for some reasons. Firstly, it could be argued that these 
early studies did not provide an adequate test of that hypothesis because they used 
such a limited assessment procedure. Secondly, acute hyperglycemia might not 
affect cognitive functioning in the absence of ketoacidosis or hyperosmolarity 
[Richardson, 1990], but not during chronic state. Thirdly, mounting evidence 
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indicates that cognitive dysfunction was a common complication of chronic 
hyperglycemia in experimental animals and in both type 1 and type 2 diabetic 
patients [Mooradian, 1988]. It was found that elderly type 2 diabetic patients with 
hyperglycemia performed more poorly than non-diabetic outpatients [Meuter et al., 
1980; Mooradian et al., 1988; Perlmuter et al., 1987; Tun et al., 1987] and 
community volunteers [Perlmuter et al., 1984] on select measures of learning, 
memory, and reaction time. Similar results have also been reported in young aduIt 
type 1 diabetic subjects with poor long-term glycemic control as evidenced by 
abnormally high levels of hemoglobin Ai�(Franceschi et cd., 1984; Ryan et al., 
1984]. So, as in other diabetic complications, the development of cognitive 
dysfunction in diabetic patients appears to be related to the level of glycemic 
control. 
Numerous reports on cognitive impairment in chronic hyperglycemia have 
been published using both behavioral and electrophysiological approaches in the 
last few years. 
Using behavioral paradigms, Flood and colleagues (1990) were the first to 
use streptozotocin-induced diabetic mice as a rodent model to study learning and 
memory during hyperglycemic state. The tasks included passive avoidance, shuttle 
box avoidance and T-maze foot shock avoidance. It was found that diabetic mice 
have better performance in step-through and step-down passive avoidance tasks. 
They acquired passive avoidance in the confined shock paradigm more readily than 
the control mice did. Besides, the performance of diabetic mice in shuttle box 
avoidance is better than that of non-diabetic control mice due to greater pain 
sensitivity of diabetic mice. The mechanism for this altered foot shock sensitivity 
( 
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may be due to a direct effect of glucose on the opioid receptor [Levine et al., 
1982]. In diabetic rats, foot shock sensitivity was not altered [Bellush and 
Rowland, 1989]. With the less-stressful T-maze foot shock avoidance task, 
acquisition did not differ between diabetic and non-diabetic mice. However, T-
maze retention was severely impaired in streptozotocin-induced diabetic mice and 
could be improved by administering insulin. This suggested that memory retention 
changes seen in diabetic mice were due to elevated glucose levels, but not the 
direct effect of streptozotocin per se [Flood et al., 1990]. In 1996，Biessels et al. 
used the streptozotocin-induced diabetic ,rat in long-term study of the place 
learning and hippocampal synaptic plasticity in hyperglycemia. The behavioral 
testing consisted of a spatial learning task in Morris water maze. It is widely used 
to test rats' abilities to learn, remember, and go to a place in space defined only by 
its position to extra maze cues. It was found that the latency and distance swum to 
reach the platform and the percentage of time spent in the border zone of the pool 
were greater in diabetes. There were no apparent differences in maze performance 
in diabetic rats with and without cataract. In 1998, Biessels et al. found that the 
insulin therapy could improve the performance of diabetic rats in the task ofMorris 
water maze. Taken together, these studies provide strong evidence that learning 
and memory could be impaired in chronic hyperglycemia. 
In electrophysiological approach, synaptic plasticity in the hippocampus is 
usually examined. In mammals, the hippocampus is involved in some specific 
forms ofbehavioral learning. In particular, the hippocampus plays a central role in 
declarative memory [Bunsey and Eichenbaum, 1996]. In rats, spatial learning is 
dependent on the integrity o f the hippocampus [Morris et al.’ 1982; Jarrard, 1995]. 
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At the cellular level, learning is thought to involve activity-dependent plastic 
modifications of synaptic strength of specific neuronal pathways [Bliss and 
Collingridge, 1993; Barnes, 1995]. One such activity-dependent modification is 
hippocampal long-term potentiation (LTP), which has been suggested as a possible 
link to memory storage processes [Massicotte and Baudry, 1991; Morris et cil., 
1986; Staubli et al., 1989]. LTP is defined as a prolonged enhancement of the 
efficacy of synaptic transmission, which can be elicited in vivo and in vitro by brief 
high-frequency stimulation (HFS) of excitatory afferents [Bliss and Collingridge, 
i> 
1993; Malenka, 1994; Grant et al., 1992]. ^A progressive deficit in the expression 
of hippocampal LTP was detected after diabetes duration of six to eight weeks. 
This LTP deficit reached a maximum after 12 weeks of diabetes and remained 
stable. Thereafter, the LTP was affected in three different sub-regions of the 
hippocampus: the dentate gyrus, CA1- and CA3-field [Kamal__e/ al., 1999]. The 
cause of LTP deficit is unknown, but could involve alterations in presynaptic 
afferent fibres, changes in transmitter release, and/or alterations at the postsynaptic 
level [Kamal et al., 1999]. The amplitude of the fibre volley was found to be 
similar in hippocampal slices from control and diabetic rats, suggesting that the 
number of afFerent fibres that was activated by the electrical stimulus was similar in 
both groups [Kamal et al., 1999]. In addition, the paired-pulse facilitation (PPF) ‘ 
was unaffected in the CAl-field in slices from diabetic rats [Biessels et al., 1996]. 
Because PPF is a form of short-term synaptic plasticity, detecting changes in the 
presynaptic processes involved in neurotransmitter release [Schulz et al., 1994; 
Zucker, 1989], these studies suggested that LTP impairment in diabetic rats is 
largely due to postsynaptic modifications rather than changes in presynaptic 
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function. However, the possibility that the activity of retrograde messengers 
involved in LTP induction, such as arachidonic acids, nitric oxide, may have been 
affected by diabetes [Biessels et al., 1996], cannot be excluded. 
Besides of LTP, long-term depression (LTD) is the second major form of 
activity-dependent synaptic plasticity that can be generated by low-frequency 
stimulation (LFS) of the SchafFer-commissural pathway in area CA1 of the 
hippocampus. Like LTP, homosynaptic LTD in hippocampal region appears to 
require NMDA receptor activation and changes in postsynaptic calcium 
It 
concentration [Artola et al., 1990; Artola and Singer, 1993; Neveu and Zucker, 
1996]. Kamal et al. (1999) found that the expression of LTD was significantly 
enhanced in hippocampal slices from 12 weeks diabetic rats as compared to 
controls. 
Changes of hippocampal LTP and LTD implicatejhat the cognitive 
functions, learning and memory, are impaired in chronic hyperglycemia. 
1.3. Common mechanisms suggested in diabetic neuropathy 
Major causal factor for the development of diabetic neuropathy is 
hyperglycemia. Several biochemical hypothesis have been proposed to explain the 
adverse effects of hyperglycemia, including polyol pathway activation [Greene et ‘ 
al., 1987], redox potential alterations [Williamson et al., 1993], nonenzymatic 
gIycation [Brownlee et al., 1988], and diacylglycerol (DAG)-protein kinase C 
(PKC) pathway activation [King et al., 1996]. 
1.3.1. PoIyol pathway activation 
15 
During hyperglycemia, the glucose concentration usually is not sufficiently 
high to produce osmotic stress [see reviewed by Feldman et al., 1997]. The excess 
glucose is rapidly converted to sorbitol by the enzyme called aldose reductase and 
sorbitol accumulation can result in a reciprocal decrease in myo-inositol and taurine 
from their low basal levels to the point that they are rate limiting for intracellular 
metabolism [Greene and Lattimer, 1982; Greene and Lattimer, 1983; Del Monte et 
al., 1991]. The accumulation of intracellular sorbitol with the compensatory 
decrease in myo-inositol is referred to as the myo-inositol depletion theory. In the 
II 
diabetic rat, myo-inositol depletion is associated with reduced Na+K+ATPase 
activity [Greene and Lattimer, 1983] and slowed motor nerve conduction velocities 
[Greene etal, 1992]. 
1.3.2. Redox potential alteration — 
Hyperglycemia-induced redox imbalance is a characteristic feature of 
poorly controlled diabetes that mimics the effects of tme hypoxia on vascular and 
neural function and plays a critical role in the pathogenesis of diabetic complication 
[Williamson et al., 1993]. As mentioned above, aldose reductase can convert the 
excess glucose to sorbitol. However, the sorbitol will then be converted to 
fructose by sorbitol dehydrogenase. Both of these reactions occur rapidly and . 
involve changes in the oxidation/reduction state of the cell [Feldman et al., 1997]. 
Conversion of glucose to sorbitol is linked to the oxidation o fNADPH to NADP+ 
while the oxidation of sorbitol to fructose is dependent on the reduction ofNAD+ 
to NADH [Greene et al., 1993]. Depletion o f N A D P H and NAD" disturbs the 
normal redox potential of the cell, resulting in several deleterious cellular 
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outcomes. Superoxide dismutase can catalyze the superoxide into hydrogen 
peroxide. Glutathione then serves as the principal mitochondrial target for 
detoxification ofhydrogen peroxide. Reduction ofhydrogen peroxide generates an 
oxidized glutathione disulfide, which in turn must be reduced by NADPH to 
generate glutathione. Hence, one of the outcomes of depletion of NADPH and 
NAD+ is the cell's inability to detoxify reactive oxygen species. If this situation 
continues, reactive oxygen will be injurious, producing lipid, DNA and protein 
peroxidation [Van Dam et al., 1995, Cameron and Cotter, 1993]. . 
^ 
1.3.3. Nonenzymatic glycosylation 
One of the central pathologic features of diabetic complications is caused 
by the hyperglycemia-accelerated formation of nonenzymatic advanced 
glycosylation end products (AGE) in tissue. In chronic hyperglycemia, excess 
glucose formed covalent linkage with primary amines of protein resulting in 
glycation products [Brownlee et al., 1988]. AGEs are irreversibly bound to 
proteins, the rate of this accumulation is proportional to the time-integrated blood 
glucose level over long periods of time. AGEs will alter the activity of enzymes, 
inhibit the regulatory molecules binding, and alter the function of nucleic acid 
[Brownlee et al., 1984]. It was found that increased nonenzymatic glycosylation 
occurs in peripheral nervous tissue of diabetic humans and animals, primarily on the 
Po-protein of peripheral nerve myelin [Vlassara et al., 1984]. In addition, a study 
showed that AGE adducts that form during long-term exposure of peripheral nerve 
myelin proteins to glucose in vitro and in vivo markedly alter the way in which 
myelin interacts with elicited macrophages. This interaction between AGE-myelin 
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and macrophages may initiate or contribute to the segmental demyelination 
associated with diabetes of peripheral nerve [Vlassara et al., 1984]. 
1.3.4. PKC alteration 
Changes in the expression and activation ofPKC has been implicated in the 
pathogenesis of diabetic neuropathy [Roberts and McLean, 1997]. In vascular 
tissues, diabetes increases DAG content, which activates PKC and causes abnormal 
tissue perfusion. Reduced nerve blood flow has been implicated in the 
development of neuropathy [Jack et al., 1999]. PKC may mediate the effects of 
nerve myo-inositol depletion on Na+K+-ATPase activity. It was found that PKC 
activity but not enzyme concentration was selectively decreased in cytosolic 
fraction prepared from sciatic nerve of streptozotocin-induced diabetic rats [Kim et 
cd., 1991]. The in situ DAG content was also reduced by 22% in the proximal 
region and by 77% in the distal region of diabetic sciatic nerve. Since DAG arises 
in large part from phosphoinositide metabolism, reduced Na+K+-ATPase activity in 
diabetic nerve is likely a consequence of decreased phosphoinositide turnover, thus 
generating insufficient DAG to maintain a PKC-mediated step necessary for 
activation ofNa+K+-ATPase [Zhu and Eichberg, 1990]. 
1.4. Do the common mechanisms of neuropathy induce the cognitive 
impairment in diabetes? 
While activation of polyol pathway is implicated to induce diabetic 
neuropathy, there is however no evidence indicating that the cognitive function is 
impaired by the alteration of polyol pathway. It was found that Na+K+-ATPase 
activity in cerebral cortex was significantly decreased in streptozotocin-induced 
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diabetic rats [Oner et al., 1997]. This activity was also decreased in 30% in 
hippocampus of diabetic rat [Leong and Leung, 1991]. However, these changes 
may not be due to the activation of polyol pathway. It was found that the sorbitol 
is accumulated in diabetic brain, but no myo-inositol depletion was observed 
[Knudsen et al., 1989]. Hence, changes in the activity of Na^K^-ATPase may due 
to the other pathway. Besides, it has been shown that changes in Na+K+-ATPase 
activity maybe involved in the development of LTP in olfactory cortex 
[Glushchenko and Izvarina, 1997], but there were no studies on cerebral cortex 
II 
and hippocampus. ^ 
Recently, some studies suggested that there is close relationship between 
oxidative stress and cognitive function. It was found that the age-related loss of 
ability to perform a spatial swim maze task was positively correlated with oxidative 
molecular damage in the cerebral cortex [Forster et al., 1996]. It was also 
suggested that generation of reactive oxygen species played a critical role in 
neuropsin transcript in the limbic areas which might be related to the disturbance in 
avoidance learning [Akita et al., 1997]. In addition, the content of glutathione and 
its synthesizing enzyme gamma-gIutamylcystetin synthase as well as superoxide 
dismutase and cataIase activities (reactive oxygen scavenging enzymes) were 
significantly decreased in diabetic brain [Bhardwaj et al., 1998]. However, the " 
exact mechanism about how these reactive oxygen species impair the cognitive 
function is still not clear. 
AGEs have been implicated in the chronic complications of diabetes 
mellitus and have been reported to play a critical role in the pathogenesis of 
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Alzheimer's disease [Sasaki et al., 1998]. However, the research about AGEs in 
cognitive function is limited. 
PKC was suggested to have a key role in learning and memory, probably 
given its involvement in synaptic plasticity pSFogues, 1997]. It was found that the 
memory and LTP are accompanied by an enhancement of the activity of PKC and 
are blocked by the inhibitors of this enzyme [Izquierdo, 1994]. PKC activity was 
found to be decreased in diabetic nerve, however, its activity in the brain [Ishii et 
al., 1998] or in the cerebral cortex [Kowluru et al., 1998; 1999] was not affected 
II 
by diabetes. Therefore, impairment of cognitive function through the PKC 
pathway is still controversial. 
Hence, impairment of the cognitive function, including learning and 
memory, in diabetes might be mediated through other specific mechanisms as 
discussed in the following sections. _ 
1.5. Structure and function of the hippocampus 
Hippocampus is made of the subiculum, the hippocampus proper, and the 
area dentata. It contains only two major cell populations. The major cell type of 
the hippocampus is the pyramidal cell, which is localized to the stratum pyramidale 
o f the hippocampus proper. The dentate gyrus may be regarded as very similar in • 
the structure to the hippocampus proper. It consists basically of a simple layer of 
granule cells [Chronister and White Jr, 1975]. The foundation of hippocampal 
architecture is the glutaminergic neurons. These principal cells (pyramidal and 
granule cells) represent 90% of hippocampal neurons, and their intra- and 
extrahippocampal areas [Vizi and Kiss, 1998]. The remaining 10% ofhippocampal 
2 0 
cells are interneurons [Freund and Buzsaki, 1996]. It has been suggested that y-
amino butyric acid (GABA) serves as a neurotransmitter for the interneurons. 
Glutamic acid decarboxylase (GAD) activity was not reduced by lesions of 
hippocampal extrinsic afFerents [Straughan, 1975], so the GABAergic system 
appears to originate from interneurons. These interneurons form an well-organized 
neural network that controls and regulates the operation of principal cell [Vizi and 
Kiss, 1998]. Within the hippocampus, there are three prominent serial synaptic 
pathways: Perforant, mossy fibre (CA3) and Schaffer collaterals (CAl).pathways. 
Input to the hippocampus originates from neurons of the entorhinal cortex by way 
of the perforant pathway, which synapses onto granule cells of the dentate gyrus. 
The granule cells send their axon (the mossy fibers) to synapse on pyramidal cells 
of the area CA3. Finally, CA3 pyramidal cells send their axons (the Schaffer 
collaterals) to other pyramidal cells in the area CA1. Damage to any one of these 
three serial pathways is thought to produce some memory impairment in humans. 
1.6. The definition and mechanism oflearning and memory 
In general, learning can be defined as the process by which new information 
about the world is acquired, and the memory represents the process by which that 
knowledge is retained [Bailey et al., 1996]. It was suggested that memory could 
be divided into at least two general categories. Explicit or declarative memory is 
the conscious recall of knowledge about people, places, and things, and is 
particularly well-developed in the vertebrate brain. Implicit or nondeclarative 
memory is the nonconscious recall of motor skills and other tasks and includes 
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simple associative forms, such as classical conditioning, and nonassociative forms, 
such as sensitization and habituation. 
Explicit memory depends on temporal lobe and diencephalic structures, 
such as hippocampus. It is most readily studied in mammals. In contrast, implicit 
memory does not depend on temporal lobe function but rather involves the same 
sensory, motor, or associational pathways used in the expression of the learning 
process. It can be effectively studied in both nonmammalian vertebrates and higher 
invertebrates [Squire, 1992]. The information stored in the brain can be assumed 
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as the changes in synaptic efficiency. This phenomenon, so-called synaptic 
plasticity, is an adaptive response of the neuron to specific external signals and 
often to the conjunction of two separate stimuli [Berridge, 1996a]. These ideas 
were refined in the late 1940s by Hebb and Konorski who proposed a coincidence-
detection rule in which the synapse linking two cells is strengthened if the cells are 
active at the same time [see review by Bliss and Collingridge, 1993]. Such 
coincidence detection is important during development to ensure that each neuron 
makes the right connections and it takes on particular significance in the 
mechanisms ofinformation processing, learning and memory [Berridge, 1996a]. 
A critical factor for the initial acquisition of information is the temporal 
coincidence of two neural inputs. When two signals combine, they lead to a large • 
increase in an intracellular messenger in very short time, usually Ca�+ or cAMP, 
which initiates the acquisition phase. This brief stimulation can bring about a 
profound change in synaptic efficacy that can persist for many hours. By coupling 
these messengers to kinases and phosphatases, the information can be stored for 
longer time periods. To form a stable and permanent memory that last for months 
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or years, it seems that the temporary processes of synaptic potentiation and 
depression have to be consolidated. This process may require the participation of 
the nucleus, with changes in gene expression and protein synthesis, to mediate the 
more permanent synaptic changes responsible for memory [Berridge, 1996a]. 
1.7. The mechanisms underlying the early and Iate phases of LTP in 
hippocampus 
In order to understand the learning and memory formation from LTP in 
hippocampus, it requires the information how LTP can be induced sdectively at 
specific synaptic sites in a neural system, which is influenced by structural and 
functional properties of the adjacent neurons. As mentioned before, there are three 
excitatory pathways to induce LTP in hippocampus, which include perforant, 
mossy fibre (CA3) and Schaffer collaterals (CA1) pathways. 
1.7.1. Perforant and Schaffer collaterals pathways 
The inductive phase of these pathways is a postsynaptic event, which 
involves calcium influx through the N-methyl-D-aspartate fNMDA) receptor 
channel, a subtype of glutamate receptors, and the recruitment of several second 
messenger pathways involving tyrosine kinases, PKC, and calcium/calmodulin 
kinase II [Bailey et al., 1996]. It has been suggested that the inductive phase of 
these pathways depends on the activation of NMDA receptors and voltage-
dependent calcium channels [Nguyen and Kandel, 1996; Pourmotabbed et al., 
1998]. In addition, the activation of NMDA receptors elicits a Ca^^ dependent 
increase in cAMP level. One role of cAMP may be to increase Ca?+ influx through 
voltage-gated Ca�+ channels [Chetkovich et al., 1991]. Besides of these early steps 
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in the postsynaptic cell, perforant and CA1 LTP also involve an enhancement of 
transmitter release from the presynaptic neuron [Bekkers and Stevens, 1990; 
Malinow and Tsien, 1990; Malgaroli and Tsien, 1992], which may be mediated by 
retrograde messenger signals that diffuse from the postsynaptic cell [0'Dell et al., 
1991; Schuman and Madison, 1991; 0'DeIl etal., 1994]. 
1.7.2. Mossy fibre pathway 
In contrast, mossy fibre LTP is much simpler. It occurs at synapses 
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between the dentate gyrus granule cells and CA3 pyramidal cells. Its inductive 
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phase occurs in presynaptic neuron. Unlike most areas of the hippocampus, 
NMDA receptor binding was very low in stratum lucidum, the termination zone of 
mossy fibres [Monaghan and Cotman, 1985]. Subsequent research suggested that 
LTP in CA3 was independent of NMDA receptor activation [Weisskopf et aL, 
1994; ViIlacres et al., 1998]. Some evidence suggested that mossy fibre LTP was 
independent of postsynaptic Ca?+ and postsynaptic membrane potential [Zalutsky 
and Nicoll, 1990], whereas other evidence indicated the opposite [Williams and 
Johnston, 1989; JafFe and Johnston, 1990; Johnston et al., 1992]. Results from 
subsequent experiments confirmed the original results ruling out postsynaptic Ca^^ 
and membrane potential in the induction mechanism of LTP [Katsuki et al., 1991; • 
Langdon et al., 1995]. Postsynaptic blockade of mossy fibre synapses by 
ionotropic glutamate receptor (iGluR) antagonists during tetanus had no effect on 
the magnitude of LTP. In contrast, removal of extracellular Ca?+ to prevent any 
Ca2+ influx into the presynaptic terminal completely blocked the induction ofLTP. 
In addition, the other second messenger that could be involved in mossy fibre LTP 
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is cAMP. Forskolin, an activator of adenylyl cyclase, caused a dramatic 
potentiation of the mossy fibre excitatory postsynaptic potential (EPSP) 
[Weisskopfe/ al., 1994]. 
Hence, the induction of CA3 LTP requires a rise in presynaptic Ca:+ and 
cAMP, and is independent of postsynaptic Ca?+ and the activation of NMDA 
receptor. 
1.7.3. Late phase ofLTP in hippocampus 
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Unlike the early phase, the mechanisms for the late phase of LTP- in all 
three regions appear to be very similar. In all three pathways, the late phase 
requires new RNA and protein synthesis, as well as the participation of protein 
kinase A (PKA). This process also involves the phosphorylation of one important 
transcription factor-- cAMP-responsive element binding protein (CREB) [Bailey et 
al., 1996] 
1.8. GABAergic interaction in hippocampal plasticity 
Although interneurons numerically represent a minority in the 
hippocampus, they can regulate different aspects of the operational modes of 
principal cells (pyramidal and granule cells) through their widespread network 
system [Buzsaki, 1997]. The current view of the role of GABAergic interneurons 
has shifted from one of merely dampening neuronal activity to that of an active role 
in information processing [Paulsen and Moser, 1998]. Accumulating evidence also 
suggests that GABAergic interneurons are important for setting the conditions for 
synaptic changes in hippocampal principal neurons during learning and memory. 
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GABA receptors are known to downregulate memory consolidation processes. 
The agonist like benzodiazepines and muscimol depress memory whereas the 
antagonist and channel blocker, bicuculline and picrotoxin, enhance it [Izquierdo 
and Medina, 1991]. The immediate post-training infusion of agonists or 
antagonists of GABAA receptors into the medial septum and dorsal hippocampus 
alters memory in rats [Izquierdo et al., 1992; Wolfman et al., 1991]. Besides, the 
late post-training infusion of muscimol, agonist of GABAA receptor, into entorhinal 
cortex also alters memory in rat [Ferreira et al., 1992]. In addition, different forms 
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of learning cause a rapid decrease of benzodiazepine-like immunoreactivity in 
hippocampus whereas infusion of benzodiazepine antagonist flumazenil into this 
region enhances memory [Izquierdo and Medina, 1991]. 
Postsynaptic GABAs receptors are also known to downregulate memory 
process. GABAe receptor blockade facilitates LTP in response to long trains of 
high-frequency stimulation [Olpe and Karlsson, 1990; Davies et al., 1991; Mott 
and Lewis, 1991; Olpe et al., 1993]. In addition, GABAe receptor antagonist 
CGP36,742 also facilitates memory in a social recognition test in rats [Mondadori 
etal., 1996], whereas GABAe receptor agonist Baclofen dose-dependently impairs 
spatial learning in rats [McNamara and Skelton, 1996]. 
Principal cells ofhippocampus are innervated by GABAergic interneurones • 
via feed-forward and feedback circuits [Paulsen and Moser, 1998]. In the 
pyramidal cell layer of CA1, GABAergic interneurones with their cell bodies 
activated in a feed-forward manner include axo-axonic cells, basket cells and bi-
stratified cells, contacting the axon initial segment, the somatic and the dendritic 
compartment of the pyramidal cell respectively [Buhl et al., 1994; Freund and 
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Buzsaki, 1996; Somogyi et al., 1983]. GABAergic feedback loops include at least 
one short loop involving basket interneurones [Buhl et al., 1994; Freund and 
Buzsaki, 1996], and at least one long loop involving horizontal cells of the stratum 
oriens-alveus, projecting to the stratum lacunosum-moleculare [Freund and 
Buzsaki, 1996; Baude et al., 1993]. Similar feed-forward and feedback loops exist 
in the dentate gyrus [Freund and Buzsaki, 1996; Halasy and Somogyi, 1993]. 
1.9. The Objective of the project 
1» 
The aim of this study was to investigate the possible effects of the chronic 
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hyperglycemia on the mRNA levels of glutamate receptors, GABA receptors, the 
synthases of retrograde messengers and calcium-related receptors and protein 
phosphatases. 
The transcripts of glutamate receptors: GluRl-7, NR2A,B, KA1 and 
mGluRl-3, GABA receptors: Aal-4, BRla, synthases of retrograde messengers: 
HO and PLA2, calcium-related receptors: calcium-sensing receptor (CSR), IP3R, 
RYR and protein phosphatases 2A and B genes were compared in the 
hippocampus ofboth control and diabetic rats by reverse transcriptase polymerase 
chain reaction (RT-PCR). 
1.10. Hypothesis 
The hippocampal biochemical cascades of learning and memory formation 
involves glutamate receptors, GABA receptors, retrograde messengers, and 
transcription factor (CREB). They might be altered in diabetes mellitus. 
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1.10.1. The initial roIe of glutamate receptors 
The biochemical events underlying memory formation of the inhibitory 
avoidance task in the hippocampus involve an activation of NMDA, a amino-3-
hydroxy-5-methyl-4-isoxalone propionate (AMPA), kainate, and metabotropic 
glutamate receptors [Izquierdo and Medina, 1997]. 
The glutamate receptors are classified into the ionotropic and metabotropic 
glutamate receptors. The ionotropic receptors are ligand-gated cation channels 
and these mediate the fast excitatory synaptic responses to glutamate. In contrast, 
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the metabotropic receptors are coupled to different second messenger systems 
through GTP-binding proteins, and these mediate the slow actions of glutamate in 
hippocampus [Gereau and Conn, 1996]. There are two main groups of ionotropic 
glutamate receptor channels activated by excitatory amino acids: NMDA and non-
NMDA receptors [Asztely and Gustafsson, 1996]. This distinction is based on the 
affinity of the receptor for glutamate selective structural analogs. The NR1, 
NR2A, B, C, D and NR3A are the subtypes of the NMDA receptor, but NR2C & 
D are not abundant in the hippocampus [Scherzer et al., 1998]. The non-NMDA 
receptors are further subdivided into AMPA and kainate receptors. AMPA 
receptors (GluRl to GluR4) are activated by AMPA with high affinity, and the 
kainate receptors (GluR5 to GluR7 and KA1 and KA2) are activated by kainate • 
with high affinity [Hammond, 1996b]. 
Within the hippocampus, the release of glutamate from presynaptic neuron 
will activate the postsynaptic glutamate receptors. This causes Ca^^ influx through 
the ionotropic receptors including KA, AMPA and NMDA receptors. Local rise in 
cytosoIic Ca2+ will trigger the release of Ca?+ from internal stores after activation of 
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Ca2+-sensitive ryanodine receptor (RYR) and inositol triphosphate receptor (IP3R) 
[Berridge, 1996b]. Besides of the ionotropic receptors, metabotropic receptors 
also play an important role in calcium signalling in hippocampus. There are eight 
subtypes of metabotropic receptors (mGluRl to mGluR8). They are grouped into 
three classes according to their amino acid sequence identity and pharmacological 
profile. They are G-protein coupled, either positively linked to phospholipase C 
(PLC) (group I) or negatively linked to adenylyl cyclase (group II and group III) 
which are known to induce phosphorylation of ionotropic glutamate receptors as 
|i 
well as modulate the excitability of neurons [Riedel et al., 1996]. Activation of 
group I mGluRs can result in activation of PLC. PLC activates 
phosphatidylinositol-4,5-bisphosphate (PIP2) to yield DAG and free inositol-1,4,5-
trisphosphate (IP3), both of which act as second messengers, IP3 leads to 
mobilization ofstored Ca^^through IP3R activation [Gereau and Conn, 1996]. The 
increasing intracellular Ca^+ is involved in the activation of kinases. In contrast, 
activation of group II and III metabotropic receptors leads to inhibition of adenyly 
cyclase function. The net result is a decrease in cAMP levels and a decrease in 
cAMP-dependent protein kinase activity [Gereau and Conn, 1996]. 
Alzheimer's disease is a progressive dementia characterized by 
deterioration of cognitive and memory function and by a pronounced • 
neurodegeneration in the entorhinal cortex, hippocampal CA1, and subiculum. It 
was found that the immunolabelling of AMPA receptor subtypes, kainate receptor 
subtypes and NMDA receptor subtype 1 in CA1 was reduced in Alzheimer's 
disease [Aronica et al., 1998]. 
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In present study, the possible downregulation of expression of ionotropic, 
group I metabotropic glutamate receptors, IP3R and RYR in diabetes mellitus 
were investigated. 
1.10.2. Involvement of putative retrograde messengers 
The putative retrograde messengers play an important role in the regulation 
ofglutamate release in the early phase of memory formation of the step-down task 
in the hippocampus [Medina and Izquicrdo, 1995]. These messengers include 
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gases such as nitric oxide QSfO) and carbon monoxide (CO); lipid mediators such as 
platelet activating factor (PAF) and arachidonic acid (AA). 
(A) The nature of the retrograde messengers 
The induction of LTP is triggered by the entry of Ca�+ through the 
glutamate receptor channels located on the postsynaptic cell_ membrane [Bliss and 
Collingridge, 1993]. However, it is very likely that the potentiated response is 
maintained, in part, by presynaptic mechanisms. To reconcile these two 
observations, it was proposed that a retrograde messenger might be released from 
the postsynaptic site of induction to initiate increased transmitter release from the 
presynaptic neuron [Bliss et al., 1986]. As a retrograde messenger, it must fullfilI 
to certain criteria. Firstly, it must be generated in postsynaptic neurons. S e c o n d l y , . 
it must pass from postsynaptic to presynaptic neurons. Thirdly, it must exert its 
effect over a short distance to preserve the synaptic specificity ofLTP. Finally, the 
half-life must be very short. For example, the half-life of NO is 4 to 6 s. It is 
consistent with the preservation of synapse specificity [Schuman and Madison, 
1991]. 
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(B) The role of the Intercellular Messengers Nitric Oxide and Carbon 
Monoxide in LTP 
The free radical gas nitric oxide is an identified neuronal messenger. It was 
found that NO acts as a neurotransmitter in the peripheral nervous system (PNS) 
[Briggs, 1992]. But in the CNS, it appears to play additional roles. NO increases 
the release of neurotransmitter in the hippocampus p^ei et al., 1996]. Most 
neurotransmitters are packaged in synaptic vesicles and released in a Ca?+-
dependent manner from specialized nerve endings, but NO is not packaged in 
vesicles, and it can diffuse from its site of production in the absence of any 
specialized release machinery. The lack' of a requirement for release apparatus 
raises the possibility that NO can be released from both pre- and postsynaptic 
neuronal elements [Schuman and Madison, 1994]. 
NO is produced by an enzyme called NO synthase fNOS). These are three 
types of nitric oxide synthases namely an inducible nitric 0xfde synthase (iNOS), a 
neuronal nitric oxide synthase (nNOS), and an endothelial nitric oxide synthase 
(eNOS). As shown in Figure 1.2a，NOS coupled with calmodulin (CaM) catalyzes 
the production of nitric oxide and L-citrulline from L-arginine in a NADPH-
dependent manner p^athan，1992]. In this process, NADPH-derived electrons are 
shuttled from flavin adeninedinucleotide (FAD) and flavin mononucleotide (FMN) 
to NOS-bound heme [Abu-Soud etal., 1994]. 
< 
” 3 1 
NOS 
NADPH+Pf|^II^^^J ^ L ^ m L - A r g , O 2 
^ ^ F A D , F M N ^BH4, Heme ^ ^ 
NADP+ < C ^ P ^ L-Citrulline,NO 
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Figure 1.2a Functional machinery o f N O synthases. See text for details. 
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Considerable evidence suggests that NO diffuses from the post- to the 
rr 
presynaptic side during the induction of LTP. Extracellular application or 
postsynaptic injection of two inhibitors of NOS, N-nitro-L-arginine (L-NARG) or 
N^-methyl-L-arginine, blocks hippocampal LTP and extracellular application of 
hemoglobin, which binds nitric oxide, also attenuates LTP [Schuman and Madison, 
1991]. In addition, it was also found that LTP was markedly reduced in knock-out 
mice lacking both eNOS and nNOS [Son et al., 1996]. Since LTP is a model for 
synaptic learning and memory mechanisms, blocking production o f N O would have 
an effect on learning and memory in animals. Learning was impaired by NOS 
inhibitor N-nitro-L-arginine (L-NARG) in a one-trial passive-avoidance task by day-
oId chicks, and injections of L-arginine prevented the effect of L-NARG by 
competing for the binding site at NOS [Holscher and Rose, 1992; 1993]. Chapman 
et al. (1992) also observed amnesia in rats in a water-maze task after injection of 
NOS inhibitor N-nitro-L-arginine methyl ester (L-NAME). Similar impairments in 
formation oflong-term memory were also observed [Estall et al., 1993; Huang and 
Lee, 1995;Bernabeu etal., 1995;Toyoda et al., 1996]. 
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Besides of nitric oxide, carbon monoxide has been recently postulated as a 
retrograde messenger in the early stages of LTP. CO is produced by an enzyme 
called heme oxygenase (HO). Recent studies have indicated that there are at least 
two isozymes o fHO, i.e., an inducible type (H0-1) and a constitutive type (HO-2) 
[Maines, 1988]. As shown in Figure 1.2b，HO coupled with cytochrome P450 
reductase (CPR) catalyzes the production of CO, iron and biliverdin from heme 
molecule. The reaction is NADPH-dependent. In this process, NADPH-derived 
electrons are transferred from FAD and FMN to heme in HO [Maine$, 1988; Bredt 
etal., 1991;Verma et al., 1993]. 严 
P-450 Reductase HO ‘ 
N — H + L T « 1 ^ ^ ^ ^ ^ ^ ^ ^ A ^ H e m e A 
N A D P + < C ^ I " ~ - • " ^ - ^ ^ = ^ Biliyerdm, 
Fe2+,C0 
Figure 1.2b Functional machinery ofheme oxygenase. See text for details. 
Carbon monoxide can enhance the release of glutamate in synapse during 
the induction of LTP. Zinc protoporphyrin IX (ZnPP), an inhibitor of the heme 
oxygenase, reduced depolarization-induced glutamate release in a calcium-
dependent manner [Shinomura et al., 1994]. Besides, ZnPP blocked induction of 
LTP in CA1 region ofhippocampal slices [Zhuo etal., 1993]. 
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Besides of the functional machinery of HO/CPR is similar to NOS/CaM, 
although the substrates (heme or L-arginine) and resulting molecules 
(CCVbiliverdin or NO/L-citrulline) are different, both the unstable gas NO and 
stable gas CO also activated guanylyl cyclase which played a role in the brain as 
biological messengers and regulators of cGMP levels [Dawson and Snyder, 1994]. 
During the induction ofLTP, the increase in Ca:+ activates HO/NOS. C 0 / ^ 0 then 
diffused randomly through cytosol and membranes, and was absorbed by heme 
group of a CO/NO-sensitive guanylate cyclase. The release of glutamate were 
increased by the production of cGMP through some unknown mechanism 
[Holscher, 1997; Verma et al., 1993; Hawkins et al., 1994]. This process will 
enhance the Ca?+ influx in postsynaptic neuron. 
(C) The role of the lipid mediators—AA and PAF in LTP 
Like NO and CO, small lipid-soluble molecules, AA. and PAF, capable of 
crossing membranes, have been shown to act as retrograde messengers in LTP 
[Bliss and Collingridge, 1993; Lynch etal., 1991; Kato etal., 1994]. 
AA is a 20-carbon unsaturated fatty acid (20:4) and is found in the sn-2 
position of membrane phospholipids [Piomelli, 1994]. AA is an intracellular 
messenger in sensory neurons [Piomelli et al., 1987] and also acts as a 
neuromodulator that is released when neuronal activity increases, such as synaptic . 
plasticity, epilepsy or hypoxia [Clements et al., 1991; Rehncrona et al., 1982]. 
PAF is a phospholipid with diverse potent physiological effects. Its actions 
are achieved at concentrations as low as 10'^^M in some systems and about 10'^M 
as an intercellular messenger [Prescott et al., 1990b]. 
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A rise in membrane concentration of free AA requires an increase in activity 
o fone or more of the enzymes responsible for its liberation from phospholipids, i.e. 
phospholipase A2 (PLA2) or PLC [Lynch et al., 1991]. At the time of induction of 
LTP in hippocampal pyramidal cells, there is a local influx of Ca^^ into the 
postsynaptic region through NMDA-receptor-associated channels, which results in 
a PLA2-dependent increase in arachidonic acid liberation [Sanfeliu et al., 1990]. 
At later time, the LTP-associated increase in glutamate release stimulates group I 
metabotropic glutamate receptors, this in turn stimulates PLC activity [Lynch et 
“ 
al., 1991], and accompany with an increase in diacylglycerol lipase, results in 
liberation of AA which accounts for the increase in release in the later, but not the 
initial, steps o fLTP [Williams etal., 1989]. 
The first evidence that AA played a critical role in LTP was suggested by 
the finding that nordihydroguaiaretic acid, a lipoxygenase and phospholipase A2 
inhibitor, blocked LTP induction [Lynch et al., 1989]. It was subsequently 
reported that AA, but not other fatty acids, induced a delayed activity-dependent 
potentiation [Williams et al., 1989]. 
Like AA, the formation of PAF is also promoted by PLA2 [Kato et al., 
1994]. It begins with the hydrolysis of a fatty acid from sn-2 position of a choline 
phosphoglyceride that has an ether-linked fatty alcohol at the sn-1 carbon. This ‘ 
reaction is catalyzed by phospholipase A2 to yield an intermediate lyso-PAF. The 
lyso-PAF then is acetylated to PAF [Prescott et al., 1990b]. In metabolic labeling 
experiments with whole cells, the synthesis of PAF via such pathway requires in 
influx of calcium [McIntyre et al., 1987; Ghigo et al., 1988]. In the hippocampus, 
PAF specially upregulated excitatory neurotransmitter release [Clark et al., 1992], 
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mobilized intracellular Ca^^ [Bito et al., 1992] and upregulated the expression of 
immediate early genes [Marcheselli and Bazan, 1994]. These findings 
demonstrated that PAF plays an important role in the hippocampal functions. In 
addition, PAF is released from neuron in culture upon electrical stimulation, 
enhances hippocampal excitatory synapses by an influence on glutamate release 
[Clark et al., 1992], and enhances hippocampal CA1 LTP [Kato et al., 1994]. A 
PAF antagonist (BN52021) that elicits neuroprotection [Panetta et al., 1987] 
actively displaces [ ^ P A F binding from presynaptic membranes [Marcheselli et 
t* 
al, 1990], blocks PAF-induced glutamate release [Clark et al., 1992], and inhibits 
LTP [Kato etal., 1994]. 
The glutamate release mechanism of AA and PAF is similar to NO/CO 
during the induction of LTP. Both AA and PAF also activate soluble guanylyl 
cyclase to produce cGMP [Zhuo et al, 1994; Calcerrada et al., 1999]. Besides, it 
was reported that NO generation is a critical step in biochemical signaling pathway 
of some cellular responses to PAF. In other words, PAF indirectly activates 
guanylyl cyclase via formation of NO [Catalan et al., 1996]. In addition, PAF 
produced LTP that might not require NMDA receptors, PAF might play the other 
role in LTP by acting on downstream of NMDA receptors in the LTP cascade 
[Kato etal., 1994]. • 
In the present studies, the possible downregulation of expression o f N O S , 
HO and PLA2 in chronic hyperglycemia were investigated. 
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1.10.3. The role ofGABA receptors 
GABA is the main inhibitory neurotransmitter in the hippocampus and has 
been implicated in the regulation oflearning and memory. There are three types of 
GABA receptors, i.e., GABAA, GABAe and GABAc. They have been 
distinguished on the basis of distinct pharmacologic and physiologic properties 
[MacdonaId and Olsen, 1994; Misgeld etcd., 1995; Johnston, 1996]. GABAA and 
GABAc receptors belong to the class ofligand-gated ion channels that mediate fast 
inhibitory postsynaptic currents lasting for milliseconds [Macdonald and Olsen, 
•t 
1994, Johnston, 1996]. In contrast, GABAB receptors are G-protein-coupled , 
receptors and they mediate slow inhibitory postsynaptic responses lasting for 
seconds [Mott, 1996], and their activation in presynaptic nerve terminals inhibits 
neurotransmitter release [Misgeld et al., 1995]. There are two types of GABA 
receptors in the hippocampus : GABAA and GABAe receptors, whereas the 
GABAc receptor is abundant in retina only. 
GABAA receptors are ionotropic receptors that are insensitive to baclofen 
and antagonized by bicuculline and picrotoxin [Pham et al., 1998]. In situ 
hybridization studies of GABAA receptor subtype mRNAs confirmed that they 
were expressed in hippocampal dentate granule cells [Wisden et al., 1992]. 
GABAA receptor is composed of several subunits: a , P, 丫，5 and p. In • 
hippocampus, GABA is synthesized by the glutamate through the enzyme glutamic 
acid decarboxylase (GAD) and is degraded by GABA transaminase (GABA-T) 
[Metcalf, 1979]. The GABA is released to synaptic cIeft by the Ca^^- dependent 
process. When the GABA is released in the synaptic cleft, it can bind to the 
GABAA receptor, or it can be taken up by presynaptic structures or by glial cells. 
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In addition, it can also dififijse away from the synaptic cleft. When two GABA 
molecules bind to GABAA receptor, the conformation of the chloride channel will 
be changed and opened for entry of chloride ions. The increased membrane 
chloride conductance will lead to inhibitory postsynaptic potential (IPSP) or 
reduction of the EPSP [Hammond, 1996a]. 
In situ hybridization studies of GABAe receptor subtype mRNAs suggested 
that they were expressed in the pyramidal cell layer of the hippocampus proper as 
well as in the granular layer of the dentate gyrus [Bischoff et al., 1999]. GABAs 
M 
receptor is G-protein-coupled to a variety of different cellular effector mechanisms. 
fT 
These different effectors enable GABAe receptor to produce not only inhibition, 
but also a variety of other effects on neuronal function. The first effector system 
that is coupled to postsynaptic GABAe receptors is voltage-dependent calcium 
channel. This channel is one of the major elements controlling the entry of calcium 
into neurons. When the GABA binds to the postsynaptic GABAs receptor, Go 
protein will then be activated. The activation of the Go, not Gi protein will inhibit 
calcium current through a direct interaction with the variety of different types of 
calcium channels, such as N-type, L-type, etc. The second effector system is 
adenylyl cyclase. AdenylyI cyclase is an enzyme responsible for converting ATP to 
cyclic AMP. cAMP then activates several different target molecules, such as . 
cAMP-dependent protein kinase, to regulate cellular functions including gene 
transcription, cellular metabolism and synaptic plasticity [Mott, 1996]. Besides, 
cAMP will activate the kinase that is responsible for phosphorylation of CREB. 
When the GABA binds to the GABAe receptor, Gi protein will be activated, then 
the activation of the Gi protein will inhibit the activity of adenylyl cyclase, so the 
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phosphorylation of CREB will be inhibited. It was confirmed that baclofen, the 
agonist of GABAe receptor, dose dependently inhibits forskolin-stimulated 
adenylyl cyclase activity [Karbon and Enna, 1985; HiIl, 1985]. The third effector 
system is potassium channels. Through these potassium channels, GABAe 
receptors hyperpolarize the membrane and reduce the input resistance of neurons. 
In the hippocampal pyramidal neurons, the GABAe receptors are linked to small-
conductance (5-12 pS) K+ channels with inward rectification [Gahwiler and Brown, 
1985; Golan et al., 1996] and mediated by G-protein [Andrade et al., 1986; 
•I 
Thalmann, 1988; Thompson and Gahwiler, 1992]. Increasing the membrane 
fT 
potassium conductance will lead to slow IPSP [De Koninck and Mody, 1997]. 
Postsynaptic GABAe receptors produce an inhibitory postsynaptic current but 
presynaptic GABAe autoreceptors inhibit the release of GABA. When GABA is 
released from the presynaptic terminal, it not only diffuses to postsynaptic 
membrane, but some amount of GABA diffijses back onto presynaptic GABAe 
receptors. When these presynaptic GABAe receptors are activated, the release of 
GABA will be suppressed. Activation of the terminal a second time, during this 
GABAs response, results in a reduced release of GABA, causing both the GABA^ 
inhibitory postsynaptic current (IPSC) and GABAe IPSC evoked by the second 
activation to be smaller [Mott, 1996]. . 
To summarize, GABA can activate both GABAA and GABAe receptors. 
Activation of GABAA receptor produce a fast, synchronous opening of chloride 
channels, resulting in a fast IPSC. However, since the GABA disappears rapidly 
from the synaptic cleft, these channels have very little opportunity to reopen. 
Therefore, whereas the activation rate of the fast IPSC is determined by the rate at 
3 9 
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which GABA binds to the GABAA receptors, the decay of this current is 
determined by the mean open time of the channels. In contrast, GABA binding to 
GABAe receptors initiates a second messenger-mediated process that is 
considerably slower, so the GABA has disappeared from the cleft before the 
GABAe receptor-mediated response even begins. Therefore, the kinetics of this 
response are determined not by the binding of GABA to the GABAe receptor but 
rather by the kinetics of the second messenger system involved. Although the 
conductance of the GABAe IPSC is small, the driving force for potassium is quite 
It 
large. In fact, because of this large driving force for potassium and the long 
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duration of the GABAe response, the GABAe IPSC can move an amount of charge 
that is close to that carried by the GABAA IPSC [Mott, 1996]. 
Since evidence suggested that diabetes could impair the synaptic plasticity 
[Biessels et al., 1996], IPSC might also be altered. If the expressions of GABAA 
and GABAe receptor are increased, IPSC will also enhanced. Hence, in the 
project, the expression GABAA and GABAe receptors under chronic 
hyperglycemia are investigated and an upregulation is expected. 
1.10.4. The role o f the CREB 
During the formation of short-term memory, the process is independent on . 
protein and RNA synthesis. It can last from minutes to few hours and involves 
only covalent modification of pre-existing proteins and an alteration of pre-existing 
connection [Bailey et al., 1996]. However, to consolidate the long term memory 
that lasts several hours to days, weeks, or even longer periods, it involves new 
mRNA and protein synthesis [Bailey et al., 1996; Davis and Squire, 1984; 
4 0 
CastelIucci et al., 1989; Frank and Greenberg, 1994; Tully et al., 1994]. One 
transcription factor CREB (cAMP-responsive element binding protein) had been 
suggested to be a molecular switch for the establishment of long-term memory 
from mollusks to mammals [Frank and Greenberg, 1994; Dale et al., 1987; Kaang 
etal., 1993; Alberini etal., 1994; Yin etal., 1994; 1995]. In the mollusc Aplysia, 
long-term facilitation of synaptic strength was blocked by injection of CRE 
oligonucleotides into the presynaptic nucleus [Dash et al., 1990; Kaang et al., 
1993; Alberini et al., 1994]. In transgenic Drosophila, long-term memory 
It 
disappeared or was augmented upon induction of repressor or activator forms of 
/r 
CREB [Tully et al., 1994，Yin et cd., 1994; 1995]. In knock out mice with deletion 
in the CREB gene, expressing a repressor form of CREB protein, it showed 
deficits in long-term memory but not in short-term memory [Bourtchuladze et al., 
1994]. 
Ca2+ influx was found to be an initial step for activation of CREB. When 
CREB was phosphorylated on Ser"3 ^y either cAMP- or Ca^^-dependent protein 
kinases [Gonzalez and Montminy, 1989; Dash et al., 1991; Sheng et al., 1991], it 
becomes active in promoting transcription from the cAMP-responsive element 
[Hunter and Karin, 1992; Chrivia et al., 1993]. In the hippocampus, Ca?+ influx 
activates the adenylyl cyclase to generate cAMP. cAMP binds to the regulatory . 
subunits of the tetrameric enzyme PKA, leading to the release of the catalytic 
subunits that translocated to the nucleus and phosphorylate the CREB [Meinkoth 
et al., 1990]. Activation of CREB then activated the transcription of immediate-
early genes (IEGs). The protein products of many IEGs are themselves 
transcription factors that can activate the transcription of late response genes, 
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perhaps acting in concert with CREB. The late response genes will be transferred 
back from the nucleus to the synapses that is necessary for long-term memory 
formation [Frank and Greenberg, 1994]. Besides of PKA, other kinases such as 
Ca^VCaM-dependent kinases I, II and IV (CaMKI, II and IV) were activated by 
Ca2+/CaM and can phosphorylate CREB on S e r ^ [Dash et al., 1991; Sheng et al., 
1991; Enslen et al., 1994; Matthews et al., 1994]. Besides, it was found that 
CaMKIV was much more potent than CaMKII in activating CREB [Sun et al., 
1994]. The influx of Ca�+ in postsynaptic hippocampal cell activated a Ca^VCaM-
it 
dependent process leading to a trans-phosphorylation of nuclear CaMKIV, possibly 
ff 
by a CaM kinase kinase. CaMKIV then phosphorylated the CREB to pCREB 
[Bito et al., 1996]. Besides, pCREB could also be dephosphorylated by nuclear 
phosphatases including protein phosphatases 1, 2A and 2B (calcineurin) [Enslen et 
al., 1994]. 
Since dephosphorylation of CREB played a critical role in consolidation of 
long-term memory, and evidence suggested that LTP be impaired in diabetes (as 
mentioned in section 1.2)，the upregulation of expressions of PP2A and PP2B is 
hypothesized in this study. 
- 4 2 
2. Materials and methods 
2.1. Animals 
Male Sprague-DawIey rats weighing 240-260 g were provided by and 
housed under specific pathogen free condition in the Laboratory Animal Services 
Centre, The Chinese University of Hong Kong. They were cared for in 
accordance with the principles and guidelines of the Animal Care and Use 
Committee of the Chinese University of Hong Kong. Animals were housed, two 
animals per cage, at 21±2°C with a 12:12-h light-dark cycle (lights on at 6 a.m.). 
Gamma ray irradiated Rodent Chow ^McoLab® Rodent Diet 20, I^MI Nutrition 
r 
International Inc, U.S.A.) and tap water were available ad libitum. 
2.1.1. Induction of diabetes meIIitus 
In this study, STZ was first dissolved in citric acid buffer at pH 4.4 and 
then injected the solution to the rats immediately. That is, the solution was freshly 
made. It was because STZ is not stable in solution and is maximally stable at pH 
4，and the stability decreases rapidly at higher or lower pH. As a result, most 
authors reported that they prepared STZ in a citrate buffer with the pH adjusted to 
pH 4.4 [Rodrigues et al., 1999]. Besides, citrate buffer could prolong the effect of 
STZ. In this study, STZ was dissolved in citric acid buffer and used for the 
subsequent injections. 
Diabetes mellitus was induced by a single intra-peritoneal injection of 
streptozotocin (75 mg/kg body weight in 0.05M citrate buffer, pH 4.4) (1.2 ml/kg 
body weight) (Sigma, U.S.A.) into treated rats (n > 6); Control rats received 
citrate buffer alone (1.2 ml/kg body weight) (normal control; n = 6). To prepare 
the 0.05M citrate buffer at pH 4.4，49.5 ml of O.lM citric acid was added to 50.5 
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ml of O.lM trisodium citrate. Before weighing streptozotocin, paper towels 
soaked with water were placed on all sides of the weighting balance. If the 
streptozotocin powder was spilled accidentally, it was trapped by wet paper. 
During weighing of streptozotocin, a mask was put on to prevent breathing in any 
of the powder. After weighing, the paper towels were placed in sealed plastic 
bags before disposal. Four days after injection, glucose concentrations were 
estimated in urine of the rats with SELF-STICK® Reagent Strips urinalysis dip 
and read strips (Chungdo Pharm. Co.,Ltd., Seoul, Korea). The test strip was 
dipped completely for no more than ls in fresh urine. No excess urine was 
A 
allowed on the test strip to avoid fault readings. The test results were compared 
carefully with the color chart on the bottle label in good light after 30-60s. Proper 
reading time (30-60s) is critical for optimal results. While comparing, the strip 
was kept in a horizontal position to avoid possible interaction of chemicals by 
excessive urine. To confirm the result, glucose concentrations were also 
measured in blood from the tail vein with Glucometer Elite® (Bayer, U.S.A.). The 
rat was placed in a rat restrainer. The tail was rubbed with 70% alcohol to 
sterilize and to dilate the vein. After sterilization, the tip of the rat's tail was cut 
by razor blade. The first drop ofblood was discarded, and then the tip of the Test 
Strip was placed on the next drop of blood, the small chamber was filled 
automatically through simple capillary action. The blood was drawn into a 
reaction chamber and a reading was displayed on the Glucometer Elite® after 30s. 
With this test, only a small amount of blood was needed. This test provides a 
quantitative measurement ofblood glucose from 1.1 to 33.3 mmol/L (20 to 600 
mg/dL). In human, the normal value is around 4.3 — 6.2 mmol fL. Then, the high 
value (high blood glucose) is about 13.6 -18.4 mmolA^. In Sprague-Dawley rat 
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(140-160 g of body weight), after 70 mgy'kg streptozotocin injection, the blood 
glucose concentration is about 23.9 mmoly^ [Tanaka et al., 1992]. 
Because the high mortality rate of diabetic rats, some special care was 
taken in dealing with these rats. Firstly, sufficient food and water had be provided 
because untreated STZ diabetic rats tended to drink a large amount of fluid and 
produce a corresponding high urine volume. Secondly, the bedding had to be 
changed more frequently because of the large volume of urine. If the bedding was 
not changed, the rats might get wet and risk losing body heat. The diarrhea that 
frequently occurs in STZ diabetic rat was an additional reason to keep the bedding 
ff 
always clean and dry [Chang et ctl., 1985], otherwise the rapid growth of 
pathogens in the bedding might affect the mortality of the rat. Finally, two rats 
had been housed per cage. The lack of sufficient space for the rats or overcrowded 
condition may lead to competition for food and result in increased and 
unnecessary morbidity and mortality. Since rats are social animals, individual 
housing was not ideal and should only be used when the experiment is required. 
In the present study, all the STZ-injected rats were kept under specific pathogen 
free condition to decrease the mortality rate. Clean and dry bedding, clean tap 
water and gamma ray irradiated Rodent Chow was provided, so frequently 
diarrhea was not evident in the rats. Two rats had been housed per cage 
throughout the experiment to minimize the non-specific stress. 
The rats were sacrificed after 4 weeks, 6 weeks, 8 weeks, 10 weeks or 12 
weeks. 
2.1.2. Insulin therapy 
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Insulin therapy was initiated 8 weeks after diabetes induction. The 
diabetic rats were divided into two groups: one group was given insulin (20 KJ/kg 
body weight, Monotard®MC, Novo Nordisk, Denmark) s.c. twice daily at 9 a.m. 
and 9 p.m. for 2 weeks and other group was given vehicle (phosphate buffer 
saline) s.c. at the same time. Before injecting the insulin, the solution was shaken 
well. To minimize stress on the rats when injecting during the dark cycle, the 
daily night doses were injected in dark under red light. The hormonal profile 
might be changed if injecting the insulin with lights on at 9 p.m. After injecting 
it 
the insulin, the user should stay a while to ensure no hypoglycemic stroke 
fT 
occurred. The units of insulin administered were decided by a preliminary study 
pFigure 3.2) in which the plasma glucose concentration was monitored every 2 
hours for 24 hours. The rats were sacrificed 10 weeks after diabetes induction. 
2.1.3. Sample collection 
To minimize the effects of changes in hormonal profile, different groups of 
rats were killed by decapitation between 9:00 a.m. and 12:00 p.m. in the morning, 
and the brains were rapidly removed and placed on top of a Petri dish lying on 
crushed ice bath. A filter paper soaked with normal saline was placed on the Petri 
dish to provide a clear background for subsequent brain dissection. The normal 
saline can prevent osmotic damage of the brain tissue. To prevent the 
temperature-dependent RNA degradation in the tissue, hippocampi were dissected 
as quickly as possible, frozen immediately in liquid nitrogen and stored in Ultra-
Low Freezer (SO-LOW, Environmental Equipment Cincinnati, Ohio, U.S.A.) at 
-70�C until total RNA extraction. At the same time, the blood was also collected 
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and microcentrifuged at 13,000 rpm for 1 minute. After microcentrifugation, the 
blood serum was stored in freezer at -20°C for future measurement ofblood. 
2.2. Isolation oftotal RNA 
RNeasy® Mini Kit provided by QIAGEN® (QIAGEN, Germany) was used 
to isolate the total RNA from the hippocampal tissue (Figure 2.1). 
The RNeasy procedure represents a novel technology for RNA isolation. 
This technology combines the selective binding properties of a silica-gel-based 
II 
membrane with the speed of microspin technology. 
r 
The frozen hippocampi were weighed and placed in a suitable sized vessel 
of the glass homogenizer as quickly as possible. BufFer RLT was added 
immediately. It is a highly denaturing guanidinium isothiocyanate (GITC)-
containing buffer which immediately inactivates RNases to ensure a high yield of 
subsequent total RNA extraction. To obtain optimal result, an appropriate volume 
ofBuffer RLT was required for efficient lysis to lyse plasma membrane. Brain is 
one of the tissues that are difficult to homogenize. The volume of lysis buffer 
might need to increase to facilitate complete homogenization and to obtain a better 
yield. Suppose the weight of starting material (i.e. hippocampus tissue) is 30 mg, 
600 p.1 ofBuffer RLT was used. P-mercaptoethanol (P-ME) were added to Buffer 
RLT before use (lOul o fp -ME per 1ml ofBuffer RLT). P- ME could inactive 
'• 4 7 
Hippocampal tissue 
I 
0 Disrupt sample and lyse ^^^ 
with GITC<ontaining buffer '！翻： 
(Buffer RLT). 夢 
1 r 
0 Homogenize sample k> shear genomic j ^ ^ 










0 Apply sampie to RNeasy spin |M Bind total RNA 
column for adsorpt ion of R N A to j p Total RNA 




0 Remove contaminants with simple [目 Wash 3 x 
wash spins (Buffers RW1 and RPE). [ j J 
^ h ^ 
.¾¾ 梦 1 r 
• ^ • " & 
it^>--<^ • 
0 Elute ready-to-use RNA in water. |g Elute 
W �J~~~Total RNA 
Figure 2.1 Flow Chart showing RNA extraction procedures by RNeasy Mini Kits 
(QIAGEN) (modified from RNeasy Mini Handbook, Qiagen) 
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RNase by denaturation of protein (by breaking the sulphur bonds). This solution 
was only stable for 1 month only. The tissue was homogenized with a 2-ml glass 
homogenizer (Kontes Glass Co., U.S.A.). Efficient homogenization of the starting 
material was essential for all intracellular RNA isolation procedures. Complete 
disruption of cellular membrane of cells and organelles was absolutely required to 
release all the RNA contained in the sample for subsequent RT-PCR. 
Homogenization is necessary to reduce the viscosity of the cell lysates produced 
by disruption and shearing of the high-molecular-weight genomic DNA and other 
high-molecular-weight cellular components to create a homogeneous lysate. In 
if * 
the presence of lysis buffer, animal tissues could be thoroughly disrupted and 
simultaneously homogenized using glass homogenizers in about 2 minutes. 
Turning the glass rod relative to the body of the homogenizer caused the sample to 
be disrupted and homogenized by a combination of turbulence and mechanical 
shearing. Foaming of the sample should be kept to a mirilmum by not plunging 
the glass rod too fast and by keeping the tip of the glass rod submerged (i.e. not 
away from the body). After homogenization, the lysate was centrifuged for 3 
minutes at maximum speed (13,000 rpm) in a microcentrifuge (MicroCentaur, 
MSE, U.S.A.). After centrifugation, the pellet was discarded, only the supernatant 
was used in subsequent steps. Equal volume of 70% ethanol was added to the 
cleared lysate. They were mixed well by pipetting. Precipitates might form after 
the addition of ethanol but this would not affect the RNeasy procedure. Ethanol 
was added to provide appropriate binding conditions (RNAs were binded to the 
membrane of spin column), which is essential in later steps. The sample (700 \x\ 
each time), including any precipitate which may have formed, was applied to an 
RNeasy mini spin column sitting on a 2-ml collection tube (it can only hold 700 i^l 
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of sample), where the total RNA could bind to the membrane and contaminants 
were efficiently washed away. It was centrifuged for 15 seconds at 10,000 rpm. 
If the volume of the mixture exceeds 700 jil, aliquots should be loaded 
successively onto the RNeasy spin column and centrifuged as mentioned above. 
The collection tube was reused but the flow-through must be discarded after each 
step. The collection tube was reused in the next step. Buffer RW1 (700 ^il) was 
pipetted onto the RNeasy column and centrifuged for 15 seconds at 10,000 rpm to 
wash the RNA. Both of the flow-through and collection tube was discarded. 
RNeasy column was transferred to a new 2-ml collection tube. Buffer RPE (500 
/f 
^il) was pipetted onto the RNeasy column and centrifuged for 15 seconds at 
10,000 rpm to wash the RNA. Since the BufFer RPE was supplied as a 
concentrate in the kit, 4 volumes of absolute ethanol were added to obtain a 
working solution before use. Flow-through was discarded and the collection tube 
was reused in next step. Buffer RPE (500 ^il) was pipetted again onto the RNeasy 
column and centrifuged for 2 minutes at maximum speed to dry the spin column. 
This step of centrifugation ensures that no ethanol was carried over during elution 
since residual ethanol may interfere with subsequent reactions. Then, the RNeasy 
spin column was detached from the collection tube carefully in order to prevent 
the contact of the spin column and the flow-through as this could result in carry-
over of ethanol. RNeasy column was then transferred into a new 1.5-ml collection 
tube. RNase-free water (55 ^il) was pipetted directly onto the RNeasy spin column 
membrane (i.e. not to the wall of the column). After standing for 10 minutes, it 
was microcentrifuged for 1 minute at 10,000 rpm to elute the RNAs. RNase-free 
water (55 ^il) was pipetted again onto the RNeasy membrane. Five minutes later, 
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it was microcentrifuged for 1 minute at 10,000 rpm to elute RNA again. To 
concentrate the total RNA, the precipitation method was used. Eluted RNA (100 
^il) and 0.1 volume o f 3 M sodium acetate (10 ^il) were pipetted onto the new 1.5-
ml collection tube. Then, 2.5 volume of ice-cold absolute ethanol (275 nl) was 
added. The mixture was placed at -70°C for about 3 hours to precipitate. After 3 
hours, it was centrifuged for 20 minutes at 10,000 g at 4°C. The supematant was 
discarded and 100 pil o f ice cold 70% ethanol was added. This step was critical to 
remove excess sodium salt. It was centrifuged again for 20 minutes at 10,000g in 
II 
4°C. The pellet (total RNA) was retained and supernatant was discarded. The 
total RNA was dried in the Speed Vacuum (DNA Speed Vac® DNA 110，Savant, 
U.S.A.) for 5 to 10 minutes, and reconstituted in 10 i^l of RNase-free water. The 
total RNA solution was stored at -70°C for subsequence analysis. Under such 
storing conditions, no degradation of mRNA has been detected, even after 1 year. 
2.3. Quantitation of total RNA 
The concentration and purity o f R N A were determined by measuring the 
absorbance at 260 nm (A260) and 280 nm (A280) in an UV-1201 UV-VIS 
Spectrophotometer (Shimadzu Corporation, Japan). Absorbance readings at 260 
nm determined RNA concentration (nucleic acid concentration) and should be • 
greater than 0.15 to ensure significance. An absorbance of 1 unit at 260 nm 
corresponds to a concentration 40 |ig of RNA per ml. This relationship is valid 
for measurements in water (i.e. using water as solvent). Therefore to quantify 
spectrophotometrically the total RNA was diluted with water. The absorbance 
readings at 280 nm measure the protein concentration. 
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An example of the calculations involved in RNA quantitation is shown below: 
Volume o f R N A sample = 10 ^1 
Dilution = 1 \x\ o f R N A sample + 99 |il ofDEPC (diethyl pyrocarbonate) treated 
water (1/100 dilution) 
Measure absorbance of diluted sample in a 1-ml cuvette 
A260 = 0.80 
When measured in water an A260 value of 1 is equal to 40 ngAnl ofRNA; 
therefore, concentration of original RNA sample = 40 x A260 x dilution factor 
= 4 0 X 0.80 X 100 “ 
“ =3200 ngAnl 
Total yield = concentration x volume of sample (ml) 
=3200 pig/ml X 0.01 ml 
= 32pig 
The ratio between the readings taken at 260 nm and 280 nm (A260/A280) 
provides an estimate of the purity of RNA. Pure RNA has an A260/A280 ratio of 
1.5-1.9 
To check the integrity and size distribution of total RNA purified with 
RNeasy, RNA was reversely transcripted to cDNA first. Then, PCR was 
proceeded with primer set that is specific for a housekeeping gene (e.g. p-actin). It 
can be checked by denaturing-agarose gel electrophoresis and ethidium bromide 
staining. If the expected sharp band of the correct size is obtained, the RNA is 
considered as intact. 
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In general, 30 p,g of total RNA was isolated in each sample (60 mg) 
(average of the wet weight of one half of the hippocampus from a young adult rat) 
through RNeasy® Mini Kit (QIAGEN, Germany). 
2.4. Reverse transcription 
The cDNA template for RT-PCR was synthesized from total RNA by 
reverse transcription. The entire population of mRNA was first converted into 
cDNA by priming with Oligo(dT). These oligonucleotides (with length between 
it 
12 and 18 nucleotides) were annealed to the Poly A tail of mRNA. In present 
study, 5 ^ig of total RNA was resuspended in 5 i^l DEPC-treated autoclaved dH2O 
in autoclaved 0.6 ml thin wall microcentrifuge tube. The autoclave procedures 
ensure a RNase free condition. One microlitre of 50 ^iM Oligo(dT)12-i8 
(Amersham Pharmacia Biotech, U.K.) was added. The volume was made up to 12 
Hl by DEPC-treated water. The RNA was denatured by heating at 70°C for 10 
minutes in thermal cycler (Peltier Thermal Cycler, PTC-100, MJ Research, USA), 
cooled on ice immediately for 2 minutes. The reverse transcription mixture of the 
following ingredients were then added: 4 pil of 5X First Strand Buffer (Gibco 
BRL, USA), 2 i^l of0 .1 M DTT (dithiothreitol) (Life Technologies, USA), 1 i^l of 
10 mM dNTPs (Life Technologies, USA) and 1 ^1 of SuperScript™ II RNase H . . 
Reverse Transcriptase (Life Technologies, USA). The enzyme has been 
engineered to eliminate the RNase activity that degrades mRNA during reaction. 
Since the enzyme is not inhibited significantly by ribosomal and transfer RNA, it 
may be used effectively to synthesize cDNA from total RNA preparation. The 
mixture was mixed well by general tapping. Then, it was incubated at 37°C for 1 
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hour, followed by heating at 90°C for 5 minutes to inactivate the enzyme. It was 
cooled to 4°C and stored it at -20°C until subsequent PCR. The amount and 
activity of the enzyme was sufficient and efficient to complete the reaction (using 
5 M-g of total RNA as template). 
2.5. PCR 
2.5.1. Preparation ofPCR 
cDNA was synthesized from 5 fig of total RNA by reverse transcription. 
As a template ofPCR, the concentration of cDNA was diluted to 20 ng/^iI. Equal 
amount of cDNA from all samples wascollected to make a large sample pool for 
later use (i.e. to prepare standard curves for the semi-quantitation). The rest of 
cDNA was aliquoted individually for PCR. 
Before performing the PCR, the conditions of reaction had to be optimized 
for the denaturing time and temperature, annealing time and temperature, 
extension time and temperature, number of PCR cycle, concentrations of cDNA 
template, primers, native Taq polymerase, and MgCl2 (e.g. 0.5 mM, 1.5 mM or 
2.0 mM). 
One critical parameter for successful amplification in PCR is the correct 
design of the oligonucleotide primers. The primers used in our laboratory (Table 
2.1) were selected or designed under the following rules. Firstly, the sequence of 
the primer had to be unique and be specific to the gene selected. Secondly, the 
self-homology of the primers was not allowed. Besides, primer length was ranged 
from 18-25 bases. In addition, G/C ratio was about 45-55%. Finally, the distance 
ofintraprimer sequence was about 100-600 bases apart. 
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Table 2.1 
Specific primer sets for the RT-PCR 
Name Sequences Number of Cycle GenBank 
base pairs number accession no . 
GluRl S 5'-AGG TTT GCT TTG TCA CAA-3' 456 25 M36418.1 
AS 5'-CTT CTC CAG GTC CTG AAA-3’ 
GluR2 S 5'-CTA TTT CCA AGG GGC GCT GAT-3' 539 24 M85035.1 
AS 5'-CAG TCC AGG ATT ACA CGC CG-3' 
GluR3 S 5'-TTC CGC TTT GCT GTG CAG-3' 468 25 M85036.2 
AS 5'-AAT GAT GCG TCT GAA TTC-3' 
GluR4 S 5'-GAA TGA ACA AGG CCT CTT GG-3' 219 27 M36421.1 
AS 5 '-TTC ATT CTC TTC GCC TCT GC-3 ’ 
GIuR5 S 5'-ATG GCA ACA GAG ACA GGT CC-3' 157 27 M83560.1 
AS 5'-AGC AGA TCC AGG CAA TAT CC-3' 
GluR6 S 5'-ATT AGG CTT GTG GAG GAT GG-3' 236 25 Z117l5.1 
AS 5 ,-GGA TTC AGG AAG GAG AAG ACG-3 ’ 
GluR7 S 5'-TCC AGT CCA TCT GCA ATG C-3' 228 30 M83552.1 
AS 5 ,-TAG ATG GAG CCA TGA TGA GC-3 ’ “ 
KA1 S 5'-CAG ACC GCC ATT GAG TAT GG-3' 202 24 X59996.1 
AS 5 ,-ACT CGT TCA TGG TGG ACT CC-3 ’ 
NR2A S 5'-TCC ATT CTT CTG TCA TCC TGC-3' 224 24 M91561.1 
AS 5 '-AAG ACC GTC TCT CAC TCT TGC-3 ’ 
NR2B S 5'-TGC ACA ATT ACT CCT CCA CG-3' 222 29 M91562.1 
AS 5，-TCC GAT TCT TCT TCT GAG CC-3 ’ 
mGluRl S 5'-CCA GTG ATG TTC TTC ATA CC-3' 361 27 M61099.1 
AS 5 ’-C AC TCT GGG TAG ACT TGA GTG-3 ’ 
mGluR2 S 5'-TTT AGG TCA GAA GCC AOA GT-3' 250 23 M92075.1 
AS 5'-CAG TAA CCA TCC TCT CTA TCC-3' 
mGluR3 S 5'-TAT TCT CAG TCC TCT GCA AG-3' 261 22 M92076.1 
AS 5'-TTG TAG CAC ATC ACT ACA TAC C-3' 
H01 S 5'-AAG GAG GTG CAC ATC CGT GCA-3' 569 27 NM_012580.1 
AS 5 '-ATG TTG AGC AGG AAG GCG GTC-3 ’ 
PLA： S 5'-TAA CGA CAG CTC TGA CAG CG-3' 298 ' 2 7 S77829.1 
AS 5'-ATT CAT CTG GAT CTG CTA CC-3' 
CSR S 5'-AAG GTC ATC TTC GGC AGT GG-3' 341 32 NM_016996.1 
AS 5 ’-GGA GTG TAA TAC GTT TTC CG-3 ’ 
IPjR S 5'-TAC TAT GGA AAC ATC AGA CC-3' 392 27 U38653.1 
AS 5 '-TGT CGC CTT GAT TTC CTG CT-3’ 
RYR2 S 5'-CAT CGG TGA TGA AAT TGA AGA-3' 130 27 U95157.1 
AS 5'-AGC ATC AAT GAT CAA ACC TTG-3' 
GABAAttl S 5'-TCA TTC TGA GCA CTC TCT CG-3' 417 22 L08490.1 
AS 5 '-TAC AGC AGT GTG CCA TCC TCT-3’ 
GABAAtt2 S 5'-TAG ACA GAC TTC TGG ATG GT-3' 300 25 L08491.1 
AS 5，-AGC AGC TTG TTT GGC ATT GT-3 ‘ 
GABAAo3 S 5'-ATG TGG CAC TTC TAT GTG ACC-3' 492 27 L08492.1 
AS 5'-GCT TGT TGG GTG TGG TCA TA-3 ‘ 
GABAAa4 S 5'-GTC CAG AAG GTA CCT GCG AT-3' 250 26 L08493.1 
AS 5，-AAA CGG GTC CAA AGC TGG TG-3 ’ 
GABAeRla S .5'-CGG AAG GTTGCCAGATTATA-3' 547 30 Y10369.1 
AS 5'-GTA GTC CGG CAG GAT GTC TCT-3' • 
GAD65 S 5'-GGA ATT GGC AGA CCA ACC GC-3' 299 24 M72422.1 
AS 5 '-TTG GAG ATG GCA CCA CCA GG-3 ‘ 
55 
Table 2.1 (Con't) 
Specific primer sets for Uie RT-PCR 
Name Sequences Number of Cycle GenBank 
base pairs number accession no. 
PP2A S 5'-AAT GCT GCT CAA TCC CCA GT-3' 450 22 NM_006243.1 
AS 5 ’-GCG TTT CCA GGC TTC CGA AG-3 ’ 
PP2B S 5'-ATC CGT ACT GGC TCC CAA AT-3' 384 19 X57115.1 




To perform PCR, reaction mixture contained 2 ^1 10x PCR buffer (IV) (200 mM 
ammouium sulphate, 750 mM Tris-HCl, pH 9.0 at 25°C and 0.1% (w/v) Tween), 
2 …ofprimers (sense and antisense) (15 ^iM), 4 i^l of cDNA template (20 ng/^il), 
0.8 fil o f 2 5 mM MgCb (if 1.0 mM is the optimal concentration), 0.4 ^1 ofdNTPs 
(10 mM), 0.5 ^1 2.5 units Taq DNA polymerase, and made up to a volume of 20 
1^1 with DEPC-treated autoclaved distilled water. The PCR reaction was carried 
out in a DNA thermal cycler (Peltier Thermal Cycler, PTC-100, MJ Research, 
USA) for optimal cycles: 9 4 � C for 1 minute followed by annealing temperature 
(varies from primers) (Table 2.2) for 1 minute and 7 2 � C for 2 minutes. After 
these, there was a cycle offinal extension at 7 2 � C for 10 minutes, and the reaction 
was terminated by lowering the temperature to 4 � C . The product could also be 
kept at 4°C for a maximum of 6 months. 
PCR products were separated by electrophoresis in 2% agarose gel 
(electrophoresis grade, Bio-Rad, USA) containing 0.5 mg/ml ethidium bromide in 
TAE buffer (40 mM Tris, 20 mM Na acetate, 1 mM EDTA, pH 7.2). Before 
electrophoresis, 1:10 Ficoll stop loading dye (1 i^l of loading dye + 9 \x\ of 
sample) (0.25% bromophenol blue, 0.25% xylene cyanol and 15% Ficoll type 400 
in H2O) had to be added into each sample. After electrophoresis, the bands were 
visualized under ultra violet (UV) light at 312 nm and an instant picture was 
usually taken for record. The band of the corrected size, as determined by 
comparison with the 100 bp DNA Ladder (Life Technologies, USA), was cut from 
the gel and purified by using USBioclean® MP Kit (USBiochem Lab, U.S.A.). 
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Table 2.2 
Condition of specific primers for the PCR 
Name [MgCl2] Annealing 
(mmol) temperature (°C ) 
GluRl 1.0 55 
GluR2 1.0 66 
GluR3 1.0 55 
GluR4 1.0 60 
GluR5 1.0 63 
GluR6 1.0 63 “ 
GluR7 1.0 “ 57 
KA1 1.0 65 
NR2A 1.0 64 
NR2B 1.0 60 ‘ 
mGluRl 2.0 ‘ 61 
mGluR2 1.0 61 
mGluR3 1.0 61 
H 0 1 1.0 68 
PLA2 1.5 61 
CSR 1.5 61 
IP3R 1.5 60 
RYR2 1.5 60 
GABAAal 1.0 63 
GABAAa2 1.0 61 
GABAA(x3 1.0 63 
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Table 2.2 (Con't) 
Condition of specific primers for the PCR 
Name [MgCb] Annealing 
(mmol) temperature ( � C ) 
GABAAa4 2.0 65 
GABAeRla 1.0 68 
GAD65 1.0 66 
PP2A 1.5 63 
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2.5.2. Purification ofPCR product 
For purification, such as removing ethidium bromide and salts, and for 
extraction the DNA from agarose, the USBioclean® MP Kit (USBiochem Lab, 
U.S.A.) was used. As mentioned in section 2.5.1, the desired DNA band was cut 
from the agarose gel under UV light. Prolonged exposure of UV light might 
destroy the desired nucleotide. The wavelength of UV light used was at 312 nm, 
with minimal destruction. The agarose block with the DNA band was then 
weighed and put into a tube with 3 volumes (1 ml/g of gel) of 6M sodium iodide 
solution. The tube with its content was incubated at 55°C for 3 to 5 minutes or 
ff 
until the agarose had melted thoroughly. To retain the whole sequence of DNA, 
prolonged incubation was avoided. Five microlitre of glass powder (up to 2.5 ^ig) 
from the USBioclean® MP Kit (USBiochem Lab, U.S.A.) was added to the 
« 
mixture (2 i^l for each i^g of agarose). The glass powder contained a specially 
formulated silica matrix that binded single and double stranded DNA only. The 
glass powder suspension was well mixed before pipetting. After adding the glass 
powder to the DNA:NaI solution, it was well mixed and stood for 5 minutes on 
ice to allow DNA to adhere. Then, it was pulsed microcentrifuged for 5 to 10 
seconds and the supernatant was discarded. The glass powder pellet was rinsed 
with 50% ethanol rinse buffer. Fifty-fold excess of buffer was used over the 
volume of glass powder used. Then, it was pulsed microcentrifuged for 5 to 10 
seconds or microcentrifuged at 3,000 rpm for 1 minute. This rinsing step was 
repeated 2 times. After final centrifugation, the rinse buffer was removed by 
USBio-pettes, an ultra-long pipette tips, as much as possible (USBio-pettes are 
very helpful in pulling the supernatant away from the glass powder pellet). The 
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glass powder pellet was resuspended in 10 i^l (for every 5 i^l of glass powder 
suspension used) of diethylpyrocarbonate (DEPC)-treated water and incubated at 
55°C for 5 minutes. After incubation, it was microcentrifuged at 3,000 rpm for 1 
minute and the supernatant containing the eluted DNA was obtained. The pellet 
was resuspended again in 5 i^l of DEPC-treated water. It was then incubated at 
55°C for 5 minutes and centrifuged at 3000 rpm for 1 minute, supernatant was 
saved. This DNA in the supernatant was later confirmed by DNA sequencing. 
II 
2.5.3. Confirmation ofPCR products by DNA sequencing 
产 
Dye Terminator Cycle Sequencing Ready Reaction Kit (PE Applied 
Biosystems, U.S.A.) was used to confirm the PCR products. The sequencing 
mixture contained 1 i^l of PCR product (i.e. cDNA template), 8 i^l of Dye 
Terminator Master Mix (dRhodamine) (PE Applied Biosystems, U.S.A.), 3.2 
pmol of upstream primer and DEPC-treated water in 20 ^1. It was heated to 96°C 
for 3 minutes and was performed in a DNA thermal cycler (Peltier Thermal 
Cycler, PTC-100, MJ Research, USA) followed by amplification for 25 cycles 
under the following conditions: 96°C for 1 minute followed by 50°C for 1 minute 
and 60°C for 4 minutes. The reaction product was loaded onto a Micro Bio-Spin® 
Chromatography Columns (Bio-Gel P-30 gel column) (Bio-Rad, USA) in order to 
remove dye terminators, unincorporated nucleotides and primer. Before use, the 
column was inverted sharply several times to resuspend the settled gel and 
bubbles were removed. The tip was snapped off and the column was placed in a 
2-ml microcentrifuge tube. The excess packing buffer was allowed to drain by 
gravity to the top of the gel bed. The drained buffer was discarded. The column 
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was then centrifuged at 1000 g for 2 minutes to remove the remaining packing 
buffer. The buffer was also discarded. Before loading sample to the column, 
buffer exchange must be performed, which 500 ml of DEPC-treated H2O was 
applied. The column was centrifuged at 1000 g for 1 minute to remove the water. 
The water from collection tube was then discarded. This step was repeated two 
more times. The column was then placed in a new 2-ml microcentrifuge tube. 
Twenty to seventy five microlitre of the sample was applied carefully directly to 
the centre of the column. Application of more or less than the recommended 
it 
sample volume might decrease column performance. After loading sample, the 
r 
column was centrifuged at 1,000 g for 4 minutes. The fraction collected was 
mixed well with an equal volume of Template Suppression Reagent (TSR) (PE 
Applied Biosystems, USA) and incubated at 95°C for 2 minutes. TSR is used to 
、 
prevent high molecular weight species from being injected into clogging the 
capillary. Finally, the tube was quickly chilled on ice, and the content was 
analyzed by using an automated DNA sequencer (ABI 310 Genetic Analyzer, 
Perkin-Elmer, U.S.A.) attached to a Macintosh PowerPC 4400/200 for data 
collection and analysis. 
The sequencing data obtained were submitted to the BLAST Sequence 
Similarity Search (KCBI, National Centre for Biotechnology Information; 
http://www.ncbi.nlm.gov/BLAST). and in all cases, the authenticity of sequences 
of genes showed in table 1 was confirmed. 
2.5.4. PCR analysis 
2.5.4.1. Quantitation ofcDNA 
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In section 2.3, the concentration of total RNA was determined by 
I measuring its absorbance at 260 nm, however, the disadvantage of this absorbance 
method was the relative insensitivity of the assay. Besides, since the reverse 
transcription is one major step that can affect the accuracy of quantification of 
I 
each sample (i.e. 5 fig of total RNA might not be transcripted to 5 i^g of cDNA), 
either normalization by housekeeping gene such as p-actin or cDNA concentration 
measurement were used to correct the discrepancies. Therefore, in the present 
study, the recently developed fluorescence (OliGreen®) probe for single strand 
I* 
DNA quantitation (Molecular Probes, USA) was used to quantify the 
ff 
concentration of cDNA in each sample. TE assay buffer (10 mM Tris-HCI, 1 mM 
EDTA at pH 7.5) (Molecular Probes, USA) was used for diluting the OliGreen 
reagent and for diluting the cDNA samples. The TE solution used had to be free 
、 
of contaminating nucleic acids because the OliGreen reagent was an extremely 
sensitive detection reagent for ssDNA. The 20X TE buffer that was included in 
the OliGreen® ssDNA Quantitation Kit was nuclease-free and nucleic acid-free. 
The IX TE working solution was prepared, by diluting (20 fold) the concentrated 
buffer with sterile, autoclaved distilled water. 
Before the sample preparation, 20 ng/^il pooled RT-products (prepared as 
mentioned in section 2.5.1 above) was used for standard curve construction 
(Figure 2.2). In present study, seven-point standard curve from 20 ng/well to 200 
ng/well was prepared. For sample preparation, 5 i^l of sample cDNA (20 ng/^il) 
was added to the well of the FluoroNunc^^ Plate fNunc, Denmark), and made up 
to a volume of 100 \x\ with IX TE buffer. Immediately before the measurement, 
an aqueous working solution of the OliGreen reagent provided with the kit was 
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Figure 2.2 The standard curve shows the fluorescence counts 
measured from the pooled cDNA ranged from 20 ng to 200 ng using 
the OliGreen ssDNA quantitation reagent. The relative amount of 
cDNA of individual sample can be determined from this standard 
curve. 
The regression R square value is 0.9983. 
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prepared by making a 200-fold dilution with TE working buffer in a plastic beaker 
that covered with foil. Then, 100 i^l of aqueous working solution of OliGreen 
reagent was added to each well of the FluoroNunc^^ Plate automatically in the 
1420 Victor-2 Multilabel Counter (EG & G Wallac, Finland). The samples were 
mixed well and incubated in the counter for 2 minutes at room temperature. After 
incubation, the sample fluorescence was measured at the excitation and the 
emission wavelengths of 480 and 520 nm respectively. The amount of cDNA of 
each sample was extrapolated from the standard curve. Then, the median of 
1» 
cDNA concentration of total samples was compared to each individual sample 
/r 
cDNA concentration. This ratio was used for future correction of subsequent PCR 
data. 
、 
2.5.4.2. Radioactive PCR 
To perform radioactive PCR, 4 i^l of cDNA sample (20ng/^il) was added to 
an autoclaved 0.6 ml thin wall reaction tube. Besides of sample, DEPC-treated 
H2O was used to make a set of 2-fold serial dilutions of the pooled cDNA sample 
as a standard curve. If the condition is optimized, no saturation of the pixels in the 
data bands will be observed in the standard curve. Therefore, preliminary PCR 
reaction with different amount of pooled cDNA sample was done first. The cycle 
number of PCR reaction was adjusted a little bit in each time until no plateau 
effect was observed in this standard curve. After optimization of cycle number of 
PCR, the whole set o fPCR with different samples could be carried on. Besides of 
cDNA template, the PCR reaction mixture contained 2 i^l of 10X PCR buffer(IV), 
2 i^l of primers (sense and antisense) (15 p,M), optimal volume of 25mM MgCl2, 
6 5 
0.4 i^l of dNTPs (lOmM), 2.5 units in 0.5 fil of native Taq DNA polymerase, 
which made to a volume of 18 p.1 with DEPC-treated water. Finally, 2 ^1 of^^P 
dCTP (0.5 ^lCi/^ll) O ^ N , U.S.A.) was added to the thin wall reaction tubes. The 
PCR reaction was carried in a DNA thermal cycler (Peltier Thermal Cycler, PTC-
100, MJ Reserch, USA) for optimal cycles: 94°C for 1 minute followed by 
annealing temperature (depend on different primers) for 1 minute and 72°C for 2 
minutes. After these, there was a cycle of final extension at 72°C for 10 minutes, 
and the reaction was terminated and the product was kept at 4°C. The PCR was 
performed in a fume hood and shielded with perspex plastic. 
2.5.4.3. cDNA gel electrophoresis 
Radioactive PCR products were separated by 8% native PAGE 
% 
(Polyacrylamide gel electrophoresis). 
30% (29:1) of acrylic acid amide (acrylamide) solution was prepared by 
first dissolving 150g of acrylic acid amide (Life Technologies, U.S.A.), then 5.17 
g of N,N ‘ -methylenebisacrylamide (Amersham Life Science, UK) in 500 ml 
distilled water. It was mixed well with magnetic stirrer, followed by filtration 
through 0.45 i^m Durapore filter paper (Milipore, USA). 
5X TBE buffer contained 54 g of Tris Base (Roche Diagnostics, 
Germany), 27.5 g of boric acid (Amersham Life Science, UK), 20 ml 0.5 M 
EDTA and made up to a volume of 1 litre with distilled water with a pH of8.0. It 
was mixed well with magnetic stirrer and followed by filtration through 0.45 fim 
Durapore (Millipore, USA). 
The working 8% polyacrylamide gel was prepared by first adding 44 ml of 
30% acrylamide solution, 33 ml of 5X TBE buffer to 88 ml of distilled water. 
t 
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Finally, 1815 fil of 10% ammonium persulfate (Bio-Rad, USA) and 192.5 i^l of 
TEMED QSF,N,N ' , N '-tetramethylethylenediamine) (Roche Diagnostics, 
Germany) were added and mixed well immediately. Then, the 8% gel solution 
was poured into the space between the two glass plates. The comb was inserted 
immediately. The acrylamide was allowed to polymerize for about half an hour at 
room temperature of 22 to 24°C. After polymerization, the comb was removed 
carefully. The wells were rinsed well with water immediately. The gel (the glass 
plates) was then assembled to the electrophoresis tank and the reservoirs of the 
|4 
tank were filled with IX TBE buffer. Before loading, the DNA samples were 
mixed with 2 [i\ of gel-loading dye (50% Glycerol, IX TAE buffer, 1% 
bromophenol blue, 1% xylene cyanol). Six hundred volts (D.C.) was usually 
applied. If electrophoresis is carried out at a higher voltage, differential heating in � 
the centre of the gel may cause bowing of the DNA bands, or melting of the 
strands of small DNA fragments, or even cracking of the glass plates. 
Electrophoresis was carried on until the dye front had migrated out (about 2.5 
hours). After electrophoresis, the gel was carefully transferred onto a sheet of 3 
MM chromatography paper (Whatman, U.K.). The gel sealed in the plastic bag 
was then exposed to the phosphor BI screen inside the GS-525 Sample Loading 
Dock for the appropriate period of time (usually 2 to 4 hours). Then, the BI 
screen was scanned and the signal intensities were quantified using the GS-525 
Molecular Imager Phosphor Imaging System (Bio-Rad, USA). The data was 
acquired and analysed by using Molecular Analyst® Software Version 1.4 (Bio-
Rad, U.S.A.). The results were exported to Microsoft Excel for future statistical 
analysis with data from other experiments. 
< 
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After reading with standard curve (Figure 2.3), the data of each sample 
was compared to its individual ratio measured from OliGreen quantitation. Then, 
the relative gene expression value of each sample was obtained (as in Figure 3.3). 
Results were presented as mean±SEM with the number of replicate experiments 
given by the value of n (n>6 in diabetic group; n=6 in control group). For 
multiple comparisons among different control and treatment groups, Bonferroni 
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Figure 2.3 Standard curve of radioactive PCR for GluRl. 
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3. Results 
The body weights of control rats and SID rats before and after STZ-
injection were summarized in Table 3.1. 
Number ofweeks after Body weight (g) of control Body weight (g) of diabetic rats 
STZ-injection rats 士 S.E. ±S.E. 
— 0 一 255 土 1.83 253 土 1.48 
— 4 一 384 土8.00 — 260士4.66 ~ ~ 
— 6 ~ ~ 454土 10.83 261 土5.91 — 
8 — 507土5.43 243 士6.38 
— 10 535 士8.47 234土7.03 
— 12 543 士8.92 233 土8.14 — 
TabIe 3.1 Body wcight of rats bcfore and aftcr STZ- injection. “ 
产 
The blood glucose concentration in the SID rats ranged from 20 - 33.3 
mmoI/L and in the control rats ranged from 4 - 7 mmol/L. 
In Figure 3.2a and 3.2b，blood glucose concentration of rats was shown ‘ 
after vehicle and insulin injection respectively. ‘ 
7 0 
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Figure 3.2a Blood glucose concentration profile after vehicle 
(phosphate buffer saline) injection (s.c.) twice daily at 9:00 a.m. and 
9:00 p.m. 
* 
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Figure 3.2b Blood glucose concentration profile after insulin (20 
IU/kg body weight) injection (s.c.) twice daily at 9:00 a.m. and 9:00 
p.m. 
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3.1. Ionotropic glutamate receptor subtypes 
To evaluate the effects of diabetes on the expression of ionotropic 
glutamate receptors, RT-PCR was performed on hippocampi of control and STZ-
induced diabetic rats (blood glucose levels > 20mmol/l) for different subtypes of 
these receptors. 
3.1.1. Non-NMDA receptors: 
3.1.1.1.AMPA receptors: 
The transcription of GluRl remained unchanged after STZ-treatment 
i* 
(Figure 3.3) but a significant main effect of time was evident OP < 0.001). No 
r 
significant interaction of treatment and time effects was observed. 
As shown in the Figure 3.4, the gene expression GluR2 mRNA remained 
unchanged after STZ-treatment. However, significant main effect of time was 
、 
observed (P < 0.001). There was no significant interaction of time and treatment. 
In Figure 3.5，no significant effect of streptozotocin on GluR3 expression 
was observed in streptozotocin-induced diabetes (SID) rats. However, significant 
time effect was observed (P < 0.001). No significant interaction between time and 
treatment was observed. 
In Figure 3.6, no significant effect of streptozotocin on GluR4 expression 
was observed in SID rats. Significant time effect (P < 0.01) but not interaction 
was observed. 
3.1.1.2.Kainate receptors: 
As shown in Figure 3.7，the transcription of the kainate receptor subtype 
GluR5 gene remained unchanged after STZ-treatment. There was a significant 
time effect (P < 0.01)，but, no significant interaction was observed. 
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Figure 3.3 Effccts of strcptozotocin ( S T Z ) treatment on transcription of G l u R l gene in the 
hippocampus of rats. 
% 
Results of two-way ANOVA: 
Treatment: F = 0.55，n.s.; Time: F = 13.77，P < 0.001; Treatment x Time: F = 1.24 n.s. 
GluR-2 
H B Control 
120 ^ ^ S T Z 
0) “ 
I 100 . 
1 ： . | ^ h l l 
. h _ • • • 
• : J l i l i i _ 
4 6 8 10 12 
Time after STZ injection (weeks) 
Figure 3.4 Effccts of strcptozotocin ( S T Z ) treatment on transcription of GluR2 gcne in the 
hippocampus of rats. 
Results of two-way ANOVA: 
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Figure 3.5 Effects of streptozotocin ( S T Z ) treatment on transcription of GluR3 gene in the 
hippocampus of rats. 
Results oftwo-way ANOVA: � 
Treatment: F = 0.67，n.s.; Time: F = 7.77，P < 0.001; Treatment x Time: F value = 2.36，n.s. 
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Figure 3.6 Effects of strcptozotocin ( S T Z ) treatment on transcription of GIuR4 gcnc in the 
hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 0.36, n.s.; Time: F = 94.35, P < 0.01; Treatment x Time: F = 1.56’ n.s. 
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Figure 3.7 Effects of strcptozotocin ( S T Z ) treatment on transcription of GIuR5 gene in the 
hip|)Ocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 0.01，n.s.; Time: F = 8.84，P < 0.01; Treatment x Time: F = 1.06’ n.s. 
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Figure 3.8 Effccts of strcptozotocin ( S T Z ) treatment on transcription of GluR6 gene in the 
hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 3.79’ n.s.; Time: F = 5.06, P < 0.01; Treatment x Time: F = 3.98，P < 0.02 
*P < 0.02 Bonferroni test after ANOVA. 
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As shown in Figure 3.8 the effect of chronic hyperglycemia on the 
expression of GluR6 was investigated. No significant treatment effect was 
observed. However, the time-course study revealed that the amount of GluR6 
mRNA was significantly reduced by 30% after 10 weeks STZ-induced diabetes (P 
< 0.02 Bonferroni test after ANOVA). Besides, significant time effect (P < 0.01) 
and interaction (P < 0.02) was also observed. 
The amount of mRNA of GluR7 remained unchanged after STZ-treatment 
(Figure 3.9). However, significant time effect was observed (P < 0.02). There 
was no significant interaction between time and treatment. 
A 
As shown in Figure 3.10，the level o f K A l mRNA was not altered after 
STZ-treatment. However, time-course study showed that there was significant 
alteration of KA1 expression after 10 weeks STZ-induced diabetes at the 
、 
transcriptional level. Pronounced decrease in KA1 mRNA (by about 40%) was 
observed (P < 0.001 Bonferroni test after ANOVA ). 'Besides, significant of time 
effect (P < 0.01) and interaction (P < 0.01) was also observed. 
3.1.2. NMDA receptors: 
Besides of AMPA and kainate receptors, NMDA receptor subtypes were 
also examined in present study. Figure 3.11 showed the effect of streptozotocin 
on the expression of one NMDA receptor subtype, NR2A, in hippocampus. It was 
found that the amount of mRNA of this receptor remained unchanged after STZ-
treatment. There was significance in time effect (P < 0.01), but not in interaction. 
In Figure 3.12，the amount of NR2B mRNA was not altered after STZ-
treatment. Significant time effect was observed (P < 0.02). However, there was 
no significant interaction between time and treatment. 
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Figure 3.9 Effects of streptozotocin ( S T Z ) treatment on transcription of GluR7 gene in the 
hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 0.07，n.s.; Time: F = 3.38，P < 0.02; Treatment x Time: F = 1.38, n.s. 
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Figure 3.10 Effccts of strcptozotocin ( S T Z ) treatment on transcription of K A 1 gcne in the 
hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 3.21’ n.s.; Time: F = 13.83, P < 0.01; Treatment x Time: F = 7.22, P < 0.01 
*P<0.001 Bonferroni test after ANOVA. 
77 




3 60 . 
丨：:nMl 
^ : _ l J x l x _ 
4 6 8 10 12 
Time after STZ injection (weeks) 
Figure 3.11 Effects of streptozotocin ( S T Z ) treatment on transcription of N R 2 A gene in the 
hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 0.22, n.s.; Time: F = 4.21, P < 0.01; Treatment x Time: F = 0.95, n.s. � 
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Figure 3.12 Effects of streptozotocin (STZ) treatment on transcription of NR2B gcne in the 
hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 0.20，n.s.; Time: F = 3.68，P < 0.02; TreaUnent x Time: F = 1.1, n.s. 
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3.2. Metabotropic glutamate receptor subtypes 
In view of the close relationship between mGluRs and calcium signalling 
in hippocampus (see Introduction), the changes of expressions of group I and II 
mGluR subtypes under chronic hyperglycemia were examined. 
3.2.1. Group I subtype (mGIuRl); 
In Figure 3.13，the amount of mGluRl mRNA was not changed in SID 
rats. The level of mRNA was significantly reduced by about 25% 10 weeks after 
STZ-treatment (P < 0.01 by Multiple comparison with Bonferroni test). 
I* 
Significant time effect (P < 0.001) and interaction between time and treatment was 
also observed(P<0.01) . 
3.2.2. Group II subtypes (mGluR2,3): 
As shown in Figure 3.14, there was significant STZ-treatment effect (P < � 
0.02) on the mRNA level of mGluR2. No significant time and interaction effects 
were observed. 
In Figure 3.15, the amount of mGluR3 mRNA remained unchanged after 
streptozotocin treatment. The amount of this group II subtype mRNA was 
significantly reduced by about 35% at week 10 (P < 0.01 by Multiple comparison 
with Bonferroni test). Besides, significant time effect (J* < 0.001) and interaction 
(P < 0.01) was observed. . 
3.3. Synthases of retrograde messengers 
• To study the effects of diabetes on retrograde messenger in the 
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F igure 3.13 Ef fects of strcptozotocin ( S T Z ) treatment on transcript ion of m G l u R l gene in 
the hippocampus of rats. 
Results oftwo-way ANOVA: 
Treatment: F = 3.09，n.s.; Time: F = 7.13，P < 0.001; Treatment x Time: F = 4.47, P < 0.01 
*P<0.01 Bonferroni test after ANOVA. � 
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F igu re 3.14 Ef fects of strcptozotocin ( S T Z ) treatment on t ranscr ipt ion of m G l u R 2 gene in 
the hi|)|)ocampus of rats. 
Results of two-way ANOVA: 
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Figure 3.15 Effccts of strcptozotocin (STZ) treatment on transcription of mGIuR3 gene in 
the hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 1.73，n.s.; Time: F = 5.91, P < 0.001; Treatment x Time: F = 4.11，P < 0.01 
*P < 0.01 Bonferroni test after ANOVA. 
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Figure 3.16 Effccts of strcptozotocin (STZ) treatment on transcription of H 0 1 gcne in the 
hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F value = 6.80，P < 0.02; Time: F value = 7.93，P < 0.001; 
Treatment x Time: F value = 3.83，P < 0.01 
•P < 0.02 Bonferroni test after ANOVA. 
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and PLA2, synthases of retrograde messenger, CO and AA, respectively, after 
STZ induced diabetes. 
In Figure 3.16，the amount o f H 0 1 mRNA was altered after STZ-treatment 
significantly (P < 0.02). A more detailed time-course study revealed that the 
amount o f m R N A was significantly reduced by 30% 10 weeks after STZ-injection 
(P < 0.02，Bonferroni test). Finally, both significant of time effect (P < 0.001) and 
interaction (P < 0.01) were also observed. 
In Figure 3.17，the expression 0 fPLA2 was altered after STZ-treatment 
1» 
significantly (P < 0.01). Time-course study also revealed that the expression of 
ff 
PLA2 was suppressed significantly by about 25% 10 weeks after STZ-injection (P 
< 0.05, Bonferroni test). Besides, There was significance in time effect (P < 
0.001) but not in interaction. 
、 
3.4. Calcium-related receptors 
As shown in Figure 3.18，there was significant treatment effect (P < 0.02) 
and time effect (P < 0.001) on the transcription of CSR gene in the hippocampus. 
However, no significant interaction between time and treatment was observed. 
In Figure 3.19, there was no significant treatment effect on IP3R mRNA. 
However,- significant time effect was observed (P < 0.001). No significant 
interaction between time and treatment was observed. 
In Figure 3.20，the level of RYR2 mRNA was not altered after STZ-
treatment. However, significant time effect was observed (P < 0.02). No 
significant interaction between time and treatment was observed. 
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Figure 3.17 Effects of streptozotocin ( S T Z ) treatment on transcription of P L A ! gene in the 
hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 9.01，P < 0.01; Time: F = 15.50, P < 0.001; Treatment x Time: F = 2.33, n.s. 
•P < 0.05 Bonferroni test after ANOVA. 
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Figure 3.18 Effccts of strcptozotocin ( S T Z ) treatment on transcription of C S R gene in the 
hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 6.44，P < 0.02; Time: F = 6.45, P < 0.001; Treatment x Time: F 二 1.55，n.s. 
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Figure 3.19 Effccts of strcptozotocin ( S T Z ) treatment on transcription of DP3R gene in the 
hippocampus of rats. 
Results of two-way ANOVA: � 
Treatment: F = 0.06，n.s.; Time: F = 6.49, P < 0.001; Treatment x Time: F = 1.95，n.s. 
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Figure 3.20 Effccts of strcptozotocin ( S T Z ) treatment on transcription of R Y R 2 gcne in the 
hippocampus of rats. 
Results oftwo-way ANOVA: 
Treatment: F = 0.51，n.s.; Time: F = 3.62, P < 0.02; Treatment x Time: F = 0.91, n.s. 
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3.5. GABA receptor subtypes (Aal-4,BRla) 
To evaluate the effect of diabetes on expression of GABA receptor in 
hippocampus, the levels of mRNA of different subtypes of GABA receptor were 
determined. 
The level of a l subtype of GABAA receptor mRNA was changed after 
STZ-treatment significantly (P < 0.001) (Figure 3.21). Time-course study showed 
that the expression of this receptor was enhanced by 55% after 8 weeks 0? < 0.05, 
Bonferroni test). Then, significant time effect was also observed 0? < 0.001). 
I* 
However, there was no significant interaction between time and treatment. 
产 
As shown in Figure 3.22, there was significant time (P < 0.05) and 
treatment effect (P < 0.05) on GABAAa2 mRNA. However, no significant 
interaction between time and treatment was observed. 
、 
In Figure 3.23, there was significant treatment effect on GABAAa3 mRNA 
(P < 0.001). Besides, a time-course study showed that the amount of GABAAOc3 
mRNA was elevated dramatically by about 70% after 4 weeks of diabetes (? < 
0.05, Bonferroni test). Two weeks later, the level of this mRNA returned to 
normal control level. The amount of this receptor was increased by 80% 10 
weeks after STZ-injection (P < 0.005，Bonferroni test). No significant time effect 
and interaction was observed. 
In Figure 3.24, the amount of GABAAa4 subtype mRNA was altered after 
STZ-treatment significantly (P < 0.001). Besides, there was significant time effect 
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Figure 3.21 Effects of streptozotocin ( S T Z ) treatment on transcription of GABAAal gene in 
the hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 18.43，P < 0.001; Time: F = 7.49，P < 0.001; Treatment x Time: F = 2.06，n.s. � 
*P < 0.05 Bonferroni test after ANOVA. 




I 120 • 
r : h i i i fc g) 
II _ i • _ ；I | i I I I I I I 
I I I I 
_ ^ _ _ j ^ — 
4 6 8 10 12 
Time after STZ injection (weeks) 
Figure 3.22 Effccts of streptozotocin ( S T Z ) treatment on transcription of GABAAa2 gcne in 
the hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 5.21, P < 0.05; Time: F = 3.07, P < 0.05; Treatment x Time: F = 2.37, n.s. 
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Figure 3.23 Effccts of strcptozotocin (STZ) treatment on transcription of GABAAOc3 gcne in 
the hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 45.63，P < 0.001; Time: F = 1.58，n.s.; Treatment x Time: F = 2.32，n.s. 
*P < 0.05 by Bonferroni test after ANOVA. t ? < 0.01 by Bonferroni test after ANOVA. � 
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Figure 3.24 Effccts of strcptozotocin (STZ) treatment on transcription of GABAAa4 gene in 
the hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 16.65, P < 0.001; Time: F = 6.74, P < 0.001; Treatment x Time: F = 0.51’ n.s. 
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In Figure 3.25，the level of GABAoRla mRNA remained unchanged after 
STZ-treatment. However, significant time effect (P < 0.001) and interaction (P < 
0.01) was observed. 
3.6. Glutamic acid decarboxylase (GAD) 
In Figure 3.26, the level of GAD65 mRNA was investigated. It was found 
that there was significant STZ-treatment effect (P < 0.01) and time effect (P < 
0.001) on the transcription of this gene in hippocampus. No significant interaction 
effect was evidenced. , 
3.7. Enzyme genes related to CREB dephosphoryIation 
To evaluate the effect of diabetes on CREB dephosphoryIation in ， 
hippocampus, mRNA levels of different subtypes .of protein phosphatase were 
determined. 
In Figure 3.27，there was significant treatment effect (P < 0.001) and time 
effect (P < 0.05) on transcription o fPP2A in hippocampus. However, there was no 
significant interaction between time and treatment. 
In Figure 3.28, there was significant treatment and time effect on the levels 
of calcineurin (PP2B) mRNA both at the level of P < 0.01’ but no significant 
interactions. 
8 8 
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Figure 3.25 Effccts of strcptozotocin ( S T Z ) treatment on transcription of G A B A s R l a gcne 
in the hippocampus of rats. 
Results of two-way ANOVA: � 
Treatment: F = 0.01，n.s.; Time: F = 12.70, P < 0.001; Treatment x Time: F = 4.51，P < 0.01 
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Figure 3.26 Effccts of strcptozotocin ( S T Z ) treatment on transcription of GAD65 gcne in the 
hippocampus of rats. 
Results oftwo-way ANOVA: 
Treatment: F = 7.88, P < 0.01; Time: F = 18.74，P < 0.001; Treatment x Time: F = 2.11，n.s. 
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Figure 3.27 Effects of streptozotocin ( S T Z ) treatment on transcription of PP2A gene in the 
hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 16.23’ P < 0.001; Time: F = 3.02，P < 0.05; Treatment x Time: F = 0.55, n.s. 
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Figure 3.28 Effects of streptozotocin ( S T Z ) treatment on transcription of calcincurin gene in 
the hippocampus of rats. 
Results of two-way ANOVA: 
Treatment: F = 9.76，P < 0.01; Time: F = 4.65，P < 0.01;Treatment x Time: F = 1.52, n.s. 
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3.8. Effect of insulin therapy on ionotropic glutamate receptor subtypes 
In Figure 3.29, the level of GluR6 mRNA was increased significantly by 
70% after 2 weeks ofinsulin therapy (P < 0.05，df = 12 unpaired Student's t-test). 
In Figure 3.30, the levels of KA1 mRNA remained unchanged after 2 
weeks ofinsulin therapy. 
3.9. Effect of insulin therapy on metabotropic glutamate receptor subtypes 
In Figure 3.31, the amount of mGIuRl mRNA was increased significantly 
by 50% after 2 weeks ofinsulin therapy (P < 0.02, df = 11 unpaired Student's t-
test). 
In Figure 3.32, the level of mGluR3 mRNA remained unchanged after 2 
weeks of insulin therapy. � 
3.10. Effect of insulin therapy on synthases of retrograde messengers 
In Figure 3.33, the levels o f H 0 1 mRNAs were increased significantly by 
30% after 2 weeks ofinsulin therapy (P < 0.05, d f = 10 unpaired Student's t-test). 
In Figure 3.34，the amount of PLA2 mRNA remained unchanged after 2 
weeks ofinsulin therapy. 
3.11. Effect of insulin therapy on GABA receptor subtype 
In Figure 3.35, the levels of GABAAa3 mRNAs remained unchanged after 
2 weeks ofinsulin therapy. 
9 1 
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Figure 3.29 Effect of insulin therapy on transcription of GIuR6 gene in the 
hippocampus of rats. 
Results of unpaired Student's t-test; P < 0.05 
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It should be noted that the molecular and functional changes observed in the 
STZ-induced diabetic rat model are considered to be the result of hyperglycemia and 
insulin deficiency, rather than a result of direct STZ toxicity on the brain. This was 
supported by the observation that in this model functional changes can be prevented 
by insulin treatment following STZ injection [Flood et al., 1990; Biessels et al., 1996; 
Kamal etal., 1999]. The question of how chronic hyperglycemia could change the 
expressions of glutamate receptor subtypes, GABA receptor subtypes, retrograde 
I* 
messenger synthases and calcium related receptors are still under investigation. 
产 
4.1. SID on glutamate receptor subtypes 
In present study, the effects of a chronic diabetic status on gene expression of 
* 
glutamate receptor subtypes in the hippocampus were investigated. The main finding 
is that the expression of the following receptors was significantly reduced: kainate 
receptor subtypes, GluR6 and KA1; mGluR subtypes, mGluRl and mGluR3. In 
contrast, the expression of mGluR2 was significantly increased. 
Recently, it has been shown that chronic ethanol [Chandler et al,, 1999] 
selectively influenced the protein level of NMDA and AMPA receptors. Transient 
ischaemia [Zhang et al., 1997] also affected the gene expression and protein level of 
NR2B, and that NMDA receptor mRNA levels also changed after estrogen treatment 
[Brann et al., 1993]. Increasing evidence show that the expressions of various 
subtypes of glutamate receptor including AMPA7KA and NMDA receptors were 
altered after epileptic seizures in hippocampus [Grigorenko et al., 1997; Ying et cd., 
1998; Pratt et al., 1993]. Some subtypes of AMPA and NMDA receptor mRNA 
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levels were also upregulated after 6-hydroxydopamine lesions in the brain [Tremblay 
etal,, 1995]. 
The question of how chronic diabetes changes the expression of specific 
glutamate receptor subtypes was investigated. In this study, the expression o f N M D A 
receptor subtypes, NR2A and NR2B, remained unchanged 4 to 12 weeks after 
treatment with STZ in the hippocampus although there was significant time effect of 
these genes. This temporal effect might be the consequence of non-specific stress 
response of the NR2A, 2B genes transcriptions. It is known that in excitatory 
%* 
synapse, the frequency-dependent Ca]+ influx is mediated largely by NMDA 
产 
receptors. As mentioned in section 1.7.1，the induction o f L T P involved the calcium 
influx through the NMDA receptor channels [Bailey et al., 1996]. It has been reported 
that both of the NMDA receptor subtype NR2B mRNA and protein levels are reduced 
、 
by about 40% in hippocampus 4 months after treatment with STZ [Di Luca et al., 
1999]. Besides, the Ca^VCaM stimulated phosphorylation of the immunoprecipitated 
NR2A/2B is also decreased in STZ-diabetic rats [Di Luca et al., 1999]. NMDA 
receptor channel opening and duration can be regulated by phosphorylation of 
specific subtypes mediated by different kinases. In particular NR2 subtypes are 
phosphorylated both by CaMKII [Omkumar et al., 1996; Gardoni et al., 1998] and by 
a tyrosine kinase [Wang et al., 1996; Moon et al., 1994]. Hence, both the suppressed 
expression o f N R 2 B subtype and the reduced CaMKII-dependent phosphorylation of 
NR2 subtypes could be involved in changes of LTP observed in suffering from 
diabetes mellitus for 4 months. No significant difference of transcription of NR2A 
and 2B even in 12 weeks after STZ-treatment in this study probably indicate that 
alteration o f N M D A receptor subtypes take a longer duration of diabetes. Deficits of 
learning and impairment of memory was observed in diabetic rats 12 weeks after 
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STZ-injection and impaired hippocampal LTP was also noted [Biessels et al., 1996]. 
Therefore, the effects of diabetes on non-NMDA receptors were also studied. 
It has been proposed that inappropriate regulation of AMPA receptor 
properties maybe involved in deficits of LTP and memory [Massicotte et al., 1991]. 
AMPA receptors may govern the early phase o f L T P deficits in diabetes. Our results 
show that the mRNA levels of AMPA receptor subtypes were not altered 12 weeks 
after STZ-induced diabetes. However, there is evidence suggesting that the binding 
affinity of AMPA receptor subtypes were reduced in hippocampus 6 weeks after STZ-
i> 
induced diabetes [Gagne et al., 1997]. Moreover, other study also revealed that 
ff 
streptozotocin administration dramatically reduced the stimulation of ^H-AMPA 
binding elicited by either treatment of brain tissue sections with calcium or by 
activation of endogenous PLA2 in rat synaptoneurosomes [Chabot et al., 1997]. 
% 
Besides, it has been found that the protein level of GluRl was reduced in 
hippocampus 6 weeks after STZ-induced diabetes [Gagne et al., 1997]. In this study, 
the mRNA levels remain unchanged even at 12 weeks after STZ-injection. It was 
found that different time after STZ-injection could alter the expression of AMPA 
subtypes in both control and diabetic rats. As illustrated in Figure 3.6，gene 
expression of GluR4 in both control and STZ-treated rats increased drastically from 
weeks 8 to 10，it might be due to the non-specific stress. 
Besides AMPA receptors, kainate receptors are also a subtype of non-NMDA 
receptors. They consist of GluR5, GluR6, GluR7, KA1 and KA2. The physiological 
and structural roles ofkainate receptors and AMAP receptors are similar. GluR5 was 
the first mammalian kainate receptor subtype to be cloned, displaying about 40% 
sequence homology to the AMPA receptor subtypes GluRl-4 [Bettler et al., 1990]. 
Its mRNA is limited mainly to CA1 region of the hippocampus. High expression 
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levels for the GluR6, GluR7, KA1 and KA2 mRNA have been demonstrated in 
hippocampus, particularly in the CA3 area [Wisden and Seeburg, 1993; Bahn et al., 
1994]. 
The present data reveal that both mRNA levels of GluR6 and KA1 are reduced 
significantly after 10 weeks of diabetes. Besides, there was a significant main effect 
of time and a significant interaction between time and STZ-treatment in the 
expression of GluR6 and KA1 genes. That is, the time after STZ-injection could alter 
the expression of these genes, and the treatment efFect might be different at various 
t< 
peroid after STZ-injection. There is no significant change of GluR5 and GluR7 
A 
mRNA in diabetes compared with yoked controls even there was significant efFect of 
time of these genes. It might be the result of non-specific stress response of the 
transcription of GluR5 and GluR7. Recently, it has been shown that pentylenetetrazol 
、 
kindling influences the binding property of kainate receptors [Luthman and Humpel, 
1997], and that mRNA levels of different subtypes of kainate receptors change after 
temporal lobe epilepsy [Mathern et al., 1998], electroconvulsive shock [Porter et al., 
1996]， kindling [Hikiji et al., 1993; Kamphuis et al., 1995] and corticosteroid 
treatment [Joels et al., 1996]. Although the mechanisms governing these changes 
remain unclear, recently the hypothesis that neurotrophins might regulate the 
expression of AMPA receptor has been put forward. In particular brain-derived 
neurotrophic factor (BDNF) upregulate the protein levels of AMPA receptors 
pSfarisawa-Saito et al., 1999]. Whether BDNF or other neurotrophins influence the 
expression ofkainate receptor subtypes is still a question? Diabetes is known to affect 
neurotrophins like nerve growth factor pSfGF), neurotrophin-3 G^T-3)，neurotrophin-4 
fNT-4)，etc., NT-3 and NT-4 mRNAs were reduced in sciatic nerve of streptozotocin-
diabetic rats [Rodriguez-Pena et al., 1995; Tomlinson et al., 1996]. Therefore, in this 
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study, suppression of GluR6 and KA1 expression 10 weeks after STZ-injection might 
be the consequence of reduced neurotrophins in diabetes. 
Are the changes in GluR6 and KA1 expressions sufficient to explain changes 
in synaptic plasticity described previously in diabetic rats? It is known that an 
imbalance between the various subtypes of kainate receptor affects the 
pharmacological and functional properties of neurons [ChittajaIlu et al., 1999]. The 
localization of kainate receptor subtypes to postsynaptic membranes frorri 
ultrastructuraI studies [Huntley et al., 1993; Petralia et al., 1994] led to the suggestion 
%* 
that they might directly contribute to excitatory postsynaptic currents. Various 
r 
physiological studies also confirmed this suggestion, e.g. kainate receptors mediated a 
slow postsynaptic current in hippocampal CA3 neurons [Castillo et al., 1997]. The 
EPSC was altered in the mutant mice with disrupted kainate receptor GluR6 gene 
* 
[Mulle et al., 1998]. In present study, the expression of GluR6 and KA1 was 
suppressed significantly 10 weeks after STZ-induced diabetes. So, it is possible to 
speculate that the EPSC might also be reduced. Hence, decrease in GluR6 and KA1 
expression might play a role in the impairment ofLTP in diabetes. 
mGluRs play an important role in a number of forms of synaptic plasticity, 
including induction of LTP in hippocampus [Yang et al., 1998]. From in situ 
hybridization, immunocytochemical and biochemical studies, multiple mGluR 
subtypes were localized in different subregions of the hippocampal formation, where 
they coupled to different second-messenger systems, including activation of 
phosphoinositide hydrolysis _ o l e t t i et al., 1986], potentiation of cAMP responses 
[Alexander et al., 1992; Winder and Conn, 1993]， inhibition of adenylyl cyclase 
[Cartmell etal., 1992; Schoepp etal., 1992] and activation ofphospholipase D [Boss 
and Conn, 1992; Boss et al., 1994; Holler et a/.，1993]. In general, group I mGluRs 
• 
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(mGluRl and mGluR5) couple to phosphoinositide hydrolysis, whereas group II 
(mGluR2 and mGluR3) and group III (mGluR4, mGluR6, mGluR7 and mGluR8) 
couple to the inhibition of adenylyl cyclase. When group I mGluRs activate G 
proteins of the Gq/n family, the activated oCqm subunit stimulates PLC, causing 
hydrolysis of membrane phosphoinositides and subsequent production of PKC 
activator DAG and the IP3 that enhance calcium release from intracellular stores. In 
contrast, activation of Gi by the group II and III mGluRs leads to an active a-subunit, 
which inhibits adenylyl cyclase. 
%t 
Substantial evidence shows that electrical kindling and intraperitoneal kainate 
injections increased the transcription of mGluRl gene [Blumcke et al., 2000]. In 
contrast, ischemia decreased mGluRl mRNA levels in hippocampus [Simonyi et al., 
1999]. In this study, the expression of mGluRl (group I receptor) was suppressed 10 
weeks after STZ-injection. Besides, there were a significant main effect of time and a 
significant interaction between time and treatment. The reduction in mGluRl mRNA 
may possibly reduce the responsive of mGluRl, leading to altered calcium release 
from intracellular stores and production of PKC. LTP might then be impaired 
because Ca:+ and PKC play a very important role in elicitation of LTP [Bliss and 
Collingridge, 1993]. Activation of group I mGluRs also increase the excitability of 
hippocampal pyramidal cells indirectly by reducing GABA-mediated inhibition [Conn 
et cd., 1998] (Figure 4.1). Downregulation of mGluRl in diabetes might increase 
GABA-mediated inhibition. Although it is known that group I mGluRs serve as 
autoreceptor at the presynaptic neuron. This autoreceptor plays an important role in 
the inhibition of glutamate release. However, immunoreactivity for the group I 
mGluRs in presynaptic elements was not detected in the hippocampus [Lujan et al., 
1 0 1 
1996]. The light microscopic findings on the distribution of mGluRs in the 
hippocampus also support the idea that the group I mGluRs is localized in 
postsynaptic element only [Shigemoto etcd., 1997]. 
Our results also revealed that there was a significant effect of STZ treatment 
on the expression of mGluR2 (group II receptor). The transcription of mGluR2 was 
increased after STZ-injection. That is, the inhibition of adenylyl cyclase might be 
increased. Besides, mGIuR2 that is localized on glia plays a role in regulating 
transmission at the SchafFer-collateral-CAl synapse by a mechanism involving 
I* 
increased cAMP accumulation and subsequent release of cAMP or cAMP metabolite 
r 
(such as adenosine) (Figure 4.1). This leads to activation of adenosine receptors on 
Schaffer collateral terminals and a decrease in glutamate release [Conn et al., 1998]. 
Therefore, upregulation of mGluR2 expression might lead to enhance the inhibition of 
、 
glutamate release from the adjacent Schaffer collateral terminal. Although activation 
of group II mGluRs mainly involved in the depression of synaptic transmission 
[Ugolini and Bordi, 1995] and might be not essential for the induction of LTP, they 
might be involved in feedback mechanisms in LTP [Behnisch et al., 1998]. In 
addition, the activation of mGluR2 blocked induction of HFS-induced LTP in rat 
hippocampus [Breakwell et al., 1998]. So, upregulation of mGluR2 expression in 
diabetes, from the present data, might impair the LTP induction. 
Reduction of mGluR3 (group II) transcription 10 weeks after STZ-injection is 
not expected. According to the working model of Conn and colleagues (1998), 
diabetes inhibits glutamate release from presynaptic neuron through the induction of 
cAMP, and release of adenosine from glial cell (Fig 4.1). Metabotropic GluRs are, 
however, considered to play an important role in the impairment o fLTP in diabetes. 
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Figure 4.1 Schematic model showing the roles of each of the major groups of 
mGluRs in area CA1 of the hippocampus (modified from Conn et al., 1998) 
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Since gene transcription might not correlate with its translation, diabetes might not 
alter the protein levels of mGluR3 even though the level of mGluR3 mRNA was 
reduced 10 weeks after STZ-injection. Differential roles for mGluRs in different 
forms of synaptic plasticity may exist, e.g. group I mGluRs play a critical role in LTP 
[Manahan-Vaughan and Reymann, 1998], whereas group II mGluRs appear to be 
important in feedback mechanism in LTP [Behnisch et al., 1998]. These findings 
were confirmed by genetic studies, e.g. LTP in mice lacking mGluRl was impaired in 
the CA1 region of hippocampus [Aiba et al., 1994]. Induction of LTP was blocked 
n 
through the action of an agonist on mGluR2 [Breakwell et al., 1998]. Hence, from 
产 
the present data, impairment ofLTP in diabetes from both downregulation ofmGluRl 
and upregulation of mGluR2 is suggested. 
From the present result, there was a possibility of additional non-specific 
% 
stress on the animals affecting the transcription of glutamate receptor subtype genes. 
This might include stress from the transportation process from animal centre to the 
laboratory, and unexpected increase in number of researcher visiting the same holding 
room during a particular period, etc. Pervious studies showed that transcription of 
glutamate receptors were sensitive to stress. It is well established that corticosteroids 
were elevated significantly by stress. For example, plasma adrenocorticotropic 
hormone and corticosterone were increased under restraint and hypertonic stress 
[Menzaghi et al., 1993]. Corticosteroid has a differential effect on the transcription of 
GluR6, KA1 and KA2 in rat hippocampus; a low dose of corticosterone resulted in an 
enhanced expression of these genes, whereas a higher dose of corticosterone resulted 
in suppressed expression of these genes [Joels et al., 1996]. In this study, the sharp 
increase GluR4 gene expression 10 weeks after STZ-injection in both STZ-treated 
and control rats might be the consequence of stress induced corticosteriod release. 
< 
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4.2. SID on Calcium-related receptors 
The mGluRl is thought to act via the phosphoinositide system with the 
associated formation of inositol 1,4,5-trisphosphate and Ca，+ release from internal 
store [Fotuhi et al., 1993]. Our results showed that the expression of mGluRl was 
suppressed in diabetes, so it is reasonable to think that the inositol 1,4,5-trisphosphate 
receptor (EP3R) expression may also be affected. However, our data demonstrated 
that this EP3R expression remained unchanged in diabetes although there was a 
significant main effect of time. The time effect might be the consequence of non-
u 
specific stress response of the transcription 0fIP3R gene. 
r 
Although regulation 0fIP3R may play a crucial role in the LTP, other calcium 
2+ 
channels can also afFect the Ca efflux from internal calcium store, and overall 
calcium mobilization may be altered. In this context, regulation of the other 
intracellular calcium channels, such as ryanodine receptor, will need to be evaluated. 
Similar to IP3R, the expression of RYR2 was found to be unchanged in diabetes 
although there was significant time effect. 
The expression of intracellular calcium receptors: EP3R and RYR at 
transcription level were examined in present study and there is no additional available 
information from literature about the expression of these receptor genes at translation 
level in diabetic rodents. Therefore, base on the present results, it is difficult to make 
suggestions about the effects of diabetes on intracellular calcium mobilization. 
Besides, localization and functional studies also showed that IP3 and ryanodine 
bindings caused the receptors to release portions of the intracellular calcium stores. 
Hence, further studies should focus on the binding properties of these receptors. 
Changes in extracellular Ca:+ could also modulate numerous neural events, 
such as the generation of action potentials, release of neurotransmitters [Parfitt and 
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Madison, 1993], gene expression e.g. immediate-early genes (IEGs) [Gallin and 
Greenberg, 1995; Ghosh et al., 1994], growth cone motility [Mattson and Kater, 
1987] and LTP [Dunwiddie and Lynch, 1979]. In this case, CSR has been studied. 
The CSR is located throughout the CNS with particular abundance in the 
hippocampus [Rogers et al., 1997]. It has been suggested that the CSR could sense 
local changes in extracellular calcium concentration, including those within synaptic 
clefts, and regulate the release of neurotransmitters and other aspects of neuronal 
functions [Brown et al., 1995]. In this study, our data demonstrate that the expression 
it 
of CSR was decreased significantly by STZ-treatment. Since the function of CSR in 
产 
brain is still not known, whether the present data suggest CSR plays a role in LTP 
impairment in diabetes require further investigation. So, other further information 
such as translational level or binding property of CSR still are needed to make 
、 
suggestions about the effects of diabetes on extracellular calcium mobilization. 
4.3. SID on Synthases of retrograde messengers 
Much interest in H 0 1 has been generated recently by reports demonstrating 
the induction of H 0 1 expression by UV irradiation, hyperoxia [Takahashi et al., 
1998], and endotoxin [Choi and Alam, 1996]. Besides, H 0 1 synthesis is also 
upregulated by a variety of non-heme inducers including heavy metals, cytokines, 
hormones and heat shock [Abraham et al., 1988; Camhi et al., 1995; Shibahara et al., 
1987]. Exposure of rats to hypoxia also markedly increased the level o f H 0 1 mRNA 
in several tissues [Lee et aI., 1997]. Focal ischemia and kainic acid-induced seizure 
also induced the expression ofheme oxygenase p^imura et al., 1996; Matsuoka etal., 
1998]. 
1 0 6 
The present study demonstrates that streptozotocin-induced diabetes 
downregulates H 0 1 expression in hippocampus 10 weeks after STZ-induced diabetes. 
Besides, significant time and treatment effects and their interaction were also found. 
The significance of decreased H01 expression under hyperglycemic conditions is not 
clearly understood. In signal transduction cascade ofhippocampal neurons, however, 
HO might play a role in CO generation more than in antioxidant activity (i.e. 
production ofbilirubin) [Haley, 1998]. Therefore, we speculate that suppression of 
H 0 1 expression in diabetes will lead to decline of CO generation in postsynaptic 
i< 
hippocampal neuron. If less CO is released from postsynaptic cell, cGMP-dependent 
产 
glutamate release in presynaptic cell will be reduced. This process finally will 
decrease the Ca!+ influx in postsynaptic cell. 
Although there are a lot of reports from molecular studies on HO, the 
% 
mechanisms governing these changes at transcriptional or even translational levels 
still remain largely unknown. A possible role of transcription factors to alter gene 
expression is now being suggested. There are several transcription factors that 
regulate the H 0 1 mRNA levels, such as activating protein-1 (AP-1), activating 
protein-2 (AP-2), nuclear factor-kappaB (NF-KB) etc pSHshio et al., 1998]. Recently, 
it has been found that NGF played an important role in regulation of transcription 
factors, NGF activates the transcription factors NF-KB and AP-1 in cultured 
sympathetic neurons. In addition, withdrawal of NGF from these cultures also 
resulted in a decline of NF-KB activity [Maggirwar et al., 1998]. As mentioned 
before, diabetes is known to affect a number of growth factors including NGF and 
insulin-like growth factor (IGF), these exists the possibility that diabetes can alter the 
expression of heme oxygenase through the downregulation of some specific 
1 0 7 
transcription factors, NF-KB and AP-1. The impairment of calcium influx in diabetes 
may be the other possibility to alter the level of heme oxygenase mRNA. As 
mentioned in section 1.10.1，the release of glutamate from presynaptic neuron causes 
postsynaptic Ca�+ influx through the ionotropic glutamate receptors including KA, 
AMPA and NMDA receptors, and this transient increase in Ca^^ might activate HO to 
release CO. Besides, calcium influx could also regulate the gene expression in 
• 2+ • neuronal cells, the rise in intracellular Ca concentration induced the transcription of 
a number of genes through transcription factors interacting with calcium response 
1« 
elements [Roche and Prentki, 1994]. Calcium influx could also regulate the 
ff 
expression of the major activity-dependent transcript of BDNF in cortical neurons 
[Shieh etal., 1998]. So, it is possible to speculate that Ca^+ influx might also regulate 
the expression of HO. In the present study, it was found that some subtypes of 
、 
glutamate receptor mRNAs were suppressed in diabetes. The Ca�+ influx might also 
be reduced. If the Ca�+ influx is impaired, lesser HO might be produced. Hence, it is 
reasonable to speculate that the mRNA level of heme oxygenase might be altered due 
to the suppression of glutamate receptor mRNAs or possibly translational product in 
diabetes. 
Besides of HO, the present results also show that the expression of 
phospholipase A2 was suppressed in diabetes after 10 weeks of diabetes. Moreover, 
significant time and treatment effects were also found. Since both the AA and PAF 
are liberated by the action 0fPLA20n their respective precursors, thus, suppression of 
PLA2 expression may conceivably lead to decrease of AA and PAF contents. 
As mentioned in section 1.10.2，the retrograde messengers can enhance the 
glutamate release in presynaptic neuron during induction of LTP [Medina and 
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Izquicrdo, 1995]. Hence, downregulation of synthases of retrograde messenger (H01 
and PLA2) mRNAs in diabetes might contribute to the impairment ofLTP. 
4.4. Sn) on GABA receptor subtypes 
GABA is the major inhibitory neurotransmitter in hippocampus and has been 
implicated in playing an important role in the induction and modulation of LTP. 
Considerable evidence shows that blockade of postsynaptic GABA receptors facilitate 
LTP. Some treatments, such as kindling [Kokaia et al,, 1994], chronic ethanol 
ii 
[Mhatre and Ticku, 1994], chronic corticosterone [Orchinik et al., 1995] or kainic 
acid-induced epilepsy [Tsunashima et al., 1997], have also been shown to induce 
changes in GABAA subtypes mRNA levels that are consistent with a change in the 
pharmacological properties of GABAA receptors. However, so far no one has directly 
investigated changes of GABA receptor expressions in response to diabetes in 
hippocampus or even in brain. The present results demonstrated that expression of 
GABAA receptor subtypes (from a l to a4) was enhanced by the streptozotocin-
induced diabetes. 
The GABAAal subtype is located throughout the dendritic areas of the 
hippocampus proper, in the strata oriens and radiatum CA1 to CA3, the stratum 
lacunosum moleculare, and in the molecular layer of the dentate gyrus [Schwarzer et 
al,, 1997]. In present study, increase in GABAAal mRNA was observed 8 weeks 
after STZ-injection. There were also significant time and treatment effects on the 
expression of this gene. The other a-subtypes (a2 and a4) is found mainly in the 
molecular layer of the dentate gyrus whereas a 3 subtype is localized in the hilus of 
the dentate gyrus [Schwarzer et cd., 1997]. Our results showed that there were 
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significant time and treatment effects on the expression of GABAAa2 in 
hippocampus. Level of the GABAAa3 mRNA was also significantly elevated 4 weeks 
and 10 weeks after STZ-injection. Besides, significant time effect and interaction 
were also found. It is not known whether such fluctuation observed in the level of 
mRNA are due to the tolerance or compensatory effects of the treatment or due to the 
non-specific stress effect on the control rats killed at 6 weeks after STZ injection. The 
present data also reveal that STZ-treatment increases the level of GABAAa4 mRNA 
significantly. There was no significant STZ-treatment effect on the expression of 
II 
GABAeRla although there were significant time effect and interaction. This might 
be the result of non-specific stress response of this gene transcription. 
In hippocampus, GABA displays a sequential participation in neuronal 
excitation in the neonatal hippocampus. It acts as an excitatory transmitter in early 
、 
postnatal stage [Ben-Ari et al., 1997]. The increase in activation of GABAA receptor 
would have toxic effect on subpopulation of developing hippocampus [Lukasiuk and 
Pitkanen, 2000]. But in adult rats, activation of GABAA receptors could induce a fast 
EPSC. As mentioned in section 1.10.3, GABAA receptors are ionotropic receptors. 
When two GABA molecules bind to GABAA receptor, the conformation of the 
chloride channel will be changed and opened for the entry of chloride ions. When the 
membrane chloride conductance increases, IPSP will be evoked [Hammond, 1996a]. 
In present study, the elevation of expressions of GABAA subtypes a l , a2, a 3 and a 4 
were observed after STZ-treatment. Besides, our results showed that there were 
significant time and STZ-treatment effects on expression of GAD65 gene. The gene 
expression of GAD65, an enzyme that synthesizes the GABA, increased significantly 
after STZ-injection. So, the release of GABA from presynaptic neuron seemed to be 
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increased. Hence, if the number of GABAA receptors is increased, the postsynaptic 
inward membrane chloride conductance will also be increased when there is an 
increase in release of GABA in the presynaptic side, i.e. if the hippocampal neurons 
are activated, the chance to evoke EPSP will be increased. Recently, it has been 
suggested that chloride influx associated with GABAA receptor activation might 
reduce GABAe IPSP amplitude significantly [Lopantsev and Schwartzkroin, 1999]. 
In the present data, transcriptions of GABAAal, 2，3 and 4 receptors, but not 
GABAeRla were increased in diabetes. It is possible to postulate that GABAe IPSP 
ii 
amplitude might be altered in diabetes. However, further information is needed to 
fT 
make a solid conclusion. 
From the present results, the elevation of expressions of GABAA subtypes 
from a l to a 4 under chronic hyperglycemia might lead to increase the membrane 
> 
chloride conductance and ultimately enabled an increase IPSP or reduction of the 
EPSP [Hammond, 1996a]. In addition, increase in activation of GABAA receptors 
suppressed the LTP formed by both priming (10 events at 100 Hz) and burst stimuli 
(4 X 10 events at 100 Hz every 20 sec) in mouse CA1 region of hippocampus 
[Seabrook et al, 1997]. It can be argued that LTP impairment in diabetes may be 
related to the upregulation of GABAAal-4 mRNAs. 
4.5. SID on enzyme genes related to dephosphorylation of CREB 
Cyclic AMP-dependent protein kinase stimulates the transcription of many 
eukaryotic genes by catalyzing the phosphorylation of the CREB. Conversely, the 
inhibition of cAMP-stimulated gene transcription would require the 
dephosphorylation of CREB by a nuclear protein phosphatase. Many studies have 
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been made towards a more complete understanding of the function of phosphatases in 
cellular signal transduction. However, there are no reports of diabetic effects on the 
expression of phosphatases using molecular approach. Hence, the expressions ofboth 
PP2A and PP2B (calcineurin) were evaluated in the present study. 
Both PP2A and calcineurin play an important role in dephosphorylation of 
CREB. In addition, PP2A is an important negative regulator of many protein kinase 
cascades. For example, it could inactivate the cAMP-dependent kinase, CaMkinase I， 
CaMkinase II or CaMkinase IV [Liauw and Steinberg, 1996; DeRemer et al., 1992; 
ii 
Barnes et al., 1995; Park and Soderling, 1995]. In this study, the transcription of 
r 
PP2A was increased significantly after STZ-injection and there was also significant 
time effect. It is reasonable to speculate that inactivation of CaMkinases especially 
CaMkinase IV might be increased in diabetes, so the CREB phosphorylation might be 
、 
decreased. Since the late phase of LTP in hippocampus requires new mRNA and 
protein synthesis which depends on the CREB phosphorylation [Bailey et al.’ 1996], 
if CREB phosphorylation decreased in diabetes, LTP would also be impaired. 
Similar to PP2A, calcineurin is also a calcium-sensitive serine/threonine 
phosphatase that is enriched at synapses and is present at high levels in hippocampus 
[Kuno et al., 1992]. Inhibition of PP2B would enhance synaptic transmission at 
synapses, and increase significantly the magnitude of synaptic potentiation during the 
induction phase of LTP [Wang and Kelly, 1996]. In the present study, the 
transcription of PP2B was increased significantly after STZ-injection and there was 
also significant time effect. So, the CREB dephosphorylation might be increased and 
LTP might be impaired in diabetes. The present data from transcriptional level do not 
allow us to determine whether the enzyme activities of PP2A and PP2B are altered, 
hence, further studies should focus on the activity of these enzymes. 
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4.6. Effect on insulin therapy on gene expression in hippocampus 
Insulin is the mainstay for treatment of virtually all Type 1 and the majority of 
Type 2 diabetic patients. Insulin may be administered intravenously or 
intramuscularly, however, long-term treatment relies predominantly on subcutaneous 
injection of the hormone. According to their duration of action, their species of origin 
(e.g. human, porcine, bovine, or a mixture of bovine and porcine) can then be 
classified into short-, intermediate-, and long-acting preparations of insulin. In the 
present study, intermediate-acting lente insulin was used to compensate the deficiency 
tt 
of insulin in diabetic rats. This porcine insulin is a mixture of crystallized and 
/^ 
amorphous insulin in an acetate buffer. The porcine insulin was selected in this study 
instead of human insulin because the duration of action of the former is longer. The 
difference may be due to less hydrophobic nature of porcine insulin, or porcine and 
% 
human insulin may interact differently with zinc crystals inside the body. The wide 
variability in the kinetics of insulin action between and even within individuals must 
be emphasized. The time to peak hypoglycemic effect and insulin levels can vary by 
±50o/o [Davis and Granner, 1996]. This variability is caused, at least in part, by large 
variations in the rate of subcutaneous absorption. Therefore, the long-acting insulin 
like protamine zinc insulin was not used because of its very unpredictable and 
prolonged course of action. 
Since the insulin (Monotard®MC, Novo Nordisk, Denmark) is a prescribed 
drug for human use, its dosage on rat should be decided first. If the dosage is too low, 
no effect will be obtained. If the dose is too high, hypoglycemia will occur. Hence, 
to find out the optimal dose, different dosages have been tested in preliminary 
experiments. Since the kinetics of subcutaneous administration of insulin does not 
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mimic the physiological secretion of insulin i.e. normal rapid rise and decline of 
insulin secretion in response to meals, the time of insulin administration should be 
determined in advance. Since lente insulin used in this study has shorter duration of 
action than long-acting insulin, twice-a-day injection regimen was used. If a higher 
dosage of insulin was given once a day, longer duration of action might be expected 
but hypoglycemic stroke might easily be occurred. If a lower dosage of insulin was 
given many times a day, this might not decrease the blood glucose level effectively 
with extra stress on animal. Hence, in present study, 20 RJ/kg body weight was found 
to be the optimal dose given twice a day (Figure 3.2). “ 
广 • 
Results from the present study show that insulin therapy can normalize the 
gene expression of GluR6, mGluRl and H 0 1 in diabetic rat to non-diabetic control 
level but cannot recover that o f K A l , mGluR3, PLA2 and GABAAa3. These findings 
、 
raise the possibility that function of ionotropic glutamate receptors, metabotropic 
glutamate receptors and retrograde messengers is restored after insulin therapy. 
Insulin therapy, which is able to nearly normalize blood glucose concentrations, body 
weights and impaired nerve conduction velocities had only a limited effect on LTP 
[Biessels et al., 1998]. Our data at the transcriptional level showing only some genes 
were recovered by insulin therapy, emphasizing the functional significance of the 
present findings. 
In present study, the transcription of different genes in hippocampus during 
chronic hyperglycemia was investigated but the encoded protein might not change in 
parallel to the mRNA [Alberts et al., 1983]. Therefore, examination of translation of 
these genes using immunohistochemistry and Western blotting can further our 
knowledge on this problem. 
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